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EXECUTIVE SUMMARY 
This paper sets out a generalised linear model (GLM) framework for the synthesis of data 
from randomised controlled trials (RCTs). We describe a common model taking the form of a 
linear regression for both fixed and random effects synthesis, that can be implemented with 
Normal, Binomial, Poisson, and Multinomial data. The familiar logistic model for meta-
analysis with Binomial data is a GLM with a logit link function, which is appropriate for 
probability outcomes. The same linear regression framework can be applied to continuous 
outcomes, rate models, competing risks, or ordered category outcomes, by using other link 
functions, such as identity, log, complementary log-log, and probit link functions. The 
common core model for the linear predictor can be applied to pair-wise meta-analysis, 
indirect comparisons, synthesis of multi-arm trials, and mixed treatment comparisons, also 
known as network meta-analysis, without distinction.  
We take a Bayesian approach to estimation and provide WinBUGS program code for a 
Bayesian analysis using Markov chain Monte Carlo (MCMC) simulation. An advantage of 
this approach is that it is straightforward to extend to shared parameter models where 
different RCTs report outcomes in different formats but from a common underlying model. 
Use of the GLM framework allows us to present a unified account of how models can be 
compared using the Deviance Information Criterion (DIC), and how goodness of fit can be 
assessed using the residual deviance. WinBUGS code for model critique is provided. Our 
approach is illustrated through a range of worked examples for the commonly encountered 
evidence formats, including shared parameter models. 
We give suggestions on computational issues that sometimes arise in MCMC evidence 
synthesis, and comment briefly on alternative software. 
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1 INTRODUCTION TO PAIRWISE & NETWORK META-ANALYSIS 
Meta-analysis, the pooling of evidence from independent sources, especially randomised 
controlled trials (RCTs) is now common in the medical research literature. There is a 
substantial literature on statistical methods for meta-analysis, going back to methods for 
combination of results from two-by-two tables,1 with the introduction of random effects 
meta-analysis2 a second important benchmark in the development of the field. Over the years 
methodological and software advances have contributed to the widespread use of meta-
analytic techniques. A series of instructional texts and reviews have appeared,3-7 and Sutton 
and Higgins8 provide a review of recent developments.  
With some exceptions,9,10 there have been few attempts to systematise the field. A wide range 
of alternative methods are employed, mostly relevant to binary and continuous outcomes. Our 
purpose here is to present a single unified account of evidence synthesis of aggregate data 
from RCTs, specifically, but not exclusively, for use in probabilistic decision making.11 In 
order to cover the variety of outcomes reported in trials and the range of data transformations 
required to achieve linearity, we adopt the framework of generalised linear modelling.12 This 
provides for Normal, Binomial, Poisson and Multinomial likelihoods, with identity, logit, log, 
complementary log-log, and probit link functions, and common core models for the linear 
predictor in both fixed effects and random effects settings.    
Indirect and mixed treatment comparisons (MTC), also known as network meta-analysis, 
represent a recent development in evidence synthesis, particularly in decision making 
contexts.13-23 Rather than pooling information on trials comparing treatments A and B, 
network meta-analysis combines data from randomised comparisons, A vs B, A vs C, A vs D, 
B vs D, and so on, to deliver an internally consistent set of estimates while respecting the 
randomisation in the evidence.24 Our common core models are designed for network meta-
analysis, and can synthesise data from pair-wise meta-analysis, multi-arm trials, indirect 
comparisons and network meta-analysis without distinction. Indeed, pair-wise meta-analysis 
and indirect comparisons are special cases of network meta-analysis.  
The common Generalised Linear Model (GLM) framework can, of course, be applied in 
either frequentist or Bayesian contexts. However, Bayesian Markov Chain Monte Carlo 
(MCMC) has for many years been the mainstay of “comprehensive decision analysis”,25 
because simulation from a Bayesian posterior distribution supplies both statistical estimation 
and inference, and a platform for probabilistic decision making under uncertainty. The freely 
available WinBUGS 1.4.3 MCMC package26 takes full advantage of the modularity afforded 
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by a GLM approach to synthesis, allowing us to present a unified treatment of the fixed and 
random effects models for meta-analysis and model critique.  
In Section 2 we present the standard Bayesian MCMC approach to pair-wise meta-analysis 
for binomial data, based on Smith et al.6. We then develop our approach to assessment of 
goodness of fit, model diagnostics and comparison based on the residual deviance and the 
Deviance Information Criterion (DIC).27 In Section 3 the GLM framework for continuous, 
Poisson, and Multinomial likelihoods is developed with identity, log, complementary log-log 
and probit link functions, with an introduction to competing risks and ordered probit models. 
Section 3.4, on continuous outcomes, describes methods for “before-after” differences. All 
these models have a separate likelihood contribution for each trial arm: in Section 3.5 we 
develop a modified core model for forms of meta-analysis in which the likelihood is based on 
a summary treatment difference and its variance. Section 4 shows how different trial 
reporting formats can be accommodated within the same synthesis in shared parameter 
models. In Section 5 the core linear predictor models for pair-wise meta-analysis are shown 
to be immediately applicable to indirect comparisons, multi-arm trials, and network meta-
analysis, without further extension. 
An extensive appendix provides code to run a series of worked examples, and fully annotated 
WinBUGS code is also available at www.nicedsu.org.uk. Section 6 provides advice on 
formulation of priors and a number of technical issues in MCMC computation.  
While Bayesian MCMC is surely the most convenient approach, particularly in decision 
making, it is certainly not the only one, and there have been a series of recent developments 
in frequentist software for evidence synthesis. These are briefly reviewed in Section 7, where 
we also outline the key issues in using frequentist methods in the context of probabilistic 
decision making. Section 8 provides some pointers to further reading, and more advanced 
extensions, and we conclude with a brief discussion. 
This technical guide is the second in a series of technical support documents on methods for 
evidence synthesis in decision making. It focuses exclusively on synthesis of relative 
treatment effect data from randomised controlled trial (RCTs). Issues such as evidence 
consistency, and the construction of models for absolute treatment effects, are taken up in 
other guides in this series (see TSDs 428 and 529). 
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2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA 
WITH LOGIT LINK 
Consider a set of M trials comparing two treatments 1 and 2 in a pre-specified target patient 
population, which are to be synthesised in a meta-analysis. A fixed effect analysis would 
assume that each study i generates an estimate of the same parameter d12, subject to sampling 
error. In a random effects model, each study i provides an estimate of the study-specific 
treatment effects δi,12 which are assumed not to be equal but rather exchangeable. This means 
that all δi,12 are ‘similar’ in a way which assumes that the trial labels, i, attached to the 
treatment effects δi,12 are irrelevant. In other words, the information that the trials provide is 
independent of the order in which they were carried out, over the population of interest.30 The 
exchangeability assumption is equivalent to saying that the trial-specific treatment effects 
come from a common distribution with mean d12 and variance 212 .  
The common distribution is usually chosen to be a normal distribution, so that 
 2,12 12 12~ ( , )i N d   (1) 
It follows that the fixed effect model is a special case of this, obtained by setting the variance 
to zero.   
Note that in the case of a meta-analysis of only two treatments the subscripts in d, δ and  are 
redundant since only one treatment comparison is being made. We shall drop the subscripts 
for , but will keep the subscripts for  and d, to allow for extensions to multiple treatments 
in Section 5.  
 
2.1 WORKED EXAMPLE: A LOGIT MODEL FOR A META-ANALYSIS OF BINOMIAL 
DATA 
Carlin31 and the WinBUGS user manual26 consider a meta-analysis of 22 trials of beta-
blockers to prevent mortality after myocardial infarction. The data available are the number 
of deaths in the treated and control arms, out of the total number of patients in each arm, for 
all 22 trials (Table 1).  
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Table 1 Blocker example: number of events and total number of patients in the control and beta-blocker 
groups for the 22 trials.31 
study 
i 
Control Treatment 
no. of events 
(ri1) 
no. of patients 
(ni1) 
no. of events 
(ri2) 
no. of patients 
(ni2) 
1 3 39 3 38 
2 14 116 7 114 
3 11 93 5 69 
4 127 1520 102 1533 
5 27 365 28 355 
6 6 52 4 59 
7 152 939 98 945 
8 48 471 60 632 
9 37 282 25 278 
10 188 1921 138 1916 
11 52 583 64 873 
12 47 266 45 263 
13 16 293 9 291 
14 45 883 57 858 
15 31 147 25 154 
16 38 213 33 207 
17 12 122 28 251 
18 6 154 8 151 
19 3 134 6 174 
20 40 218 32 209 
21 43 364 27 391 
22 39 674 22 680 
2.1.1 Model specification 
Defining rik as the number of events (deaths), out of the total number of patients in each arm, 
nik, for arm k of trial i, we assume that the data generation process follows a Binomial 
likelihood i.e.  
 ~ Binomial( , )ik ik ikr p n  (2) 
where pik represents the probability of an event in arm k of trial i (i=1,…,22; k=1,2). 
Since the parameters of interest, pik, are probabilities and therefore can only take values 
between 0 and 1, a transformation (link function) is used that maps these probabilities into a 
continuous measure between plus and minus infinity. For a Binomial likelihood the most 
commonly used link function is the logit link function (see Table 3). We model the 
probabilities of success pik on the logit scale as 
13 
 
 ,1 { 1}logit( )ik i i k kp I     (3) 
where 
 { }
1 if  is true
0 otherwiseu
u
I  

  
In this setup, i  are trial-specific baselines, representing the log-odds of the outcome in the 
‘control’ treatment (i.e. the treatment indexed 1), ,12i  are the trial-specific log-odds ratios of 
success on the treatment group (2) compared to control (1). We can write equation (3) as 
 1
2 ,12
logit( )
logit( )
i i
i i i
p
p

 

 
  
where, for a random effects model the trial-specific log-odds ratios come from a common 
distribution: 2,12 12~ ( , )i N d  . For a fixed effect model we replace equation (3) with 
 12 { 1}logit( )ik i kp d I      
which is equivalent to setting the between-trial heterogeneity 2 to zero thus assuming 
homogeneity of the underlying true treatment effects. 
An important feature of all the meta-analytic models presented here is that no model is 
assumed for the trial-specific baselines i . They are regarded as nuisance parameters which 
are estimated in the model. An alternative is to place a second hierarchical model on the trial 
baselines, or to put a bivariate normal model on both.32,33 However, unless this model is 
correct, the estimated relative treatment effects will be biased. Our approach is therefore 
more conservative, and in keeping with the widely used frequentist methods in which relative 
effect estimates are treated as data (see Section 3.5) and baselines eliminated entirely. 
Baseline models are discussed in TSD5.29 
2.1.2 Model fit and model comparison 
To check formally whether a model’s fit is satisfactory, we will consider an absolute measure 
of fit: the overall residual deviance: resD . This is the posterior mean of the deviance under the 
current model, minus the deviance for the saturated model,12 so that each data point should 
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contribute about 1 to the posterior mean deviance.27,34 We can then compare the value of resD  
to the number of independent data points to check if the model fit can be improved. For a 
Binomial likelihood each trial arm contributes 1 independent data point and the residual 
deviance is calculated as  
 
2 log ( ) log
ˆ ˆ
     dev
ik ik ik
res ik ik ik
i k ik ik ik
ik
i k
r n rD r n r
r n r
    
           



 (4) 
where rik and nik are the observed number of events and patients in each trial arm, iˆk ik ikr n p  
is the expected number of events in each trial arm calculated at each iteration, based on the 
current model, and devik is the deviance residual for each data point calculated at each 
iteration. This is then summarised by the posterior mean: resD . 
Leverage statistics are familiar from frequentist regression analysis where they are used to 
assess the influence that each data point has on the model parameters. The leverage for each 
data point, leverageik, is calculated as the posterior mean of the residual deviance minus the 
deviance at the posterior mean of the fitted values. For a Binomial likelihood, letting ikr  be 
the posterior mean of iˆkr , and ikdev  the posterior mean of devik, 
 ik ikD ik
i k i k
p leverage dev dev        
where  ikdev  is the posterior mean of the deviance calculated by replacing iˆkr  with ikr  in 
equation (4). 
The Deviance Information Criterion (DIC)27 is the sum of the posterior mean of the residual 
deviance, resD , and the leverage, pD, (also termed the effective number of parameters). The 
DIC provides a measure of model fit that penalises model complexity – lower values of the 
DIC suggest a more parsimonious model. The DIC is particularly useful for comparing 
different parameter models for the same likelihood and data, for example fixed and random 
effects models or fixed effect models with and without covariates. 
If the deviance residuals provide indications that the model does not fit the data well, 
leverage plots can give further information on whether poorly fitting data points are having a 
material effect on the model parameters. Leverage plots show each data point’s contribution 
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to pD (leverageik) plotted against their contribution to resD  ( ikdev ) and can be used to check 
how each point is affecting the overall model fit and DIC. It is useful to display these 
summaries in a plot of leverageik vs wik for each data point, where ikikw dev  , with sign 
given by the sign of  ˆik ikr r  to indicate whether the data is over- or under-estimated by the 
model. Curves of the form 2x y c  , c=1,2,3,…, where x represents wik and y represents the 
leverage, are marked on the plots and points lying on such parabolas each contribute an 
amount c to the DIC.27 Points which lie outside the lines with c=3 can generally be identified 
as contributing to the model’s poor fit. Points with a high leverage are influential, which 
means that they have a strong influence on the model parameters that generate their fitted 
values.  
Leverage plots for the fixed and random effects models are presented in Figure 1 and Figure 
2, respectively. From these the random effects model appears to be more appropriate as 
points lie closer to the centre of the plot. To further examine the model fit at individual data 
points, inspection of ikdev  for all i and k will highlight points with a high residual deviance, 
over 2 say, as accounting for the lack of fit. This can help identify data points that fit poorly. 
WinBUGS will calculate pD and the posterior mean of the deviance for the current model D , 
but will not output the contributions of the individual data points to the calculations. 
Furthermore, without subtracting the deviance for the saturated model, D  is hard to interpret 
and can only be useful for model comparison purposes and not to assess the fit of a single 
model. Therefore users wishing to produce leverage plots such as those in Figure 1 and 
Figure 2 need to calculate the contributions of individual studies to resD  and to the leverage 
themselves. The latter needs to be calculated outside WinBUGS, for example in R or 
Microsoft Excel. The pD , and therefore the DIC, calculated in the way we suggest is not 
precisely the same as that calculated in WinBUGS, except in the case of a normal likelihood. 
This is because WinBUGS calculates the fit at the mean value of the parameter values, while 
we propose the fit at the mean value of the fitted values. The latter is more stable in highly 
non-linear models with high levels of parameter uncertainty. 
In this document we suggest that global DIC statistics and resD  are consulted both to compare 
fixed and random effect models, and to ensure that overall fit is adequate. Leverage plots may 
be used to identify influential and/or poorly fitting observations. Guidance on choice of fixed 
or random effects model, an issue that is closely bound up with the impact of sparse data and 
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choice of prior distributions, is given in Section 6. In network meta-analysis there are 
additional issues regarding consistency between evidence sources on different contrasts. This 
is discussed fully in TSD4.28  
2.1.3 WinBUGS implementation and illustrative results 
Annotated WinBUGS 1.4.3 code is shown in the Appendix, for both a random effects model 
and a fixed effect model (Blocker Examples 1(c) and 1(d)). Included in the description of the 
code are some additional comments on alternative priors, and additional code that can be 
used when there are more than two treatments being compared, to rank the treatments, or 
compute the probability that each is the best treatment. We ran both fixed and random effects 
models, and some of the results, including the resD  and DIC statistics, are shown in Table 2. 
All results are based on 20,000 iterations on 3 chains, after a burn-in of 10,000. 
Table 2 Blocker example: posterior mean, standard deviation (sd), median and 95% Credible interval 
(CrI) for both the fixed and random effects models for the treatment effect d12, absolute effects of the 
placebo (T1) and beta-blocker (T2) for a mean mortality of -2.2 and precision 3.3 on the logit scale; 
heterogeneity parameter  and model fit statistics. 
Fixed Effect model Random Effects model 
mean sd median CrI mean sd median CrI 
d12 -0.26 0.050 -0.26 (-0.36,-0.16) -0.25 0.066 -0.25 (-0.38,-0.12) 
T1 0.11 0.055 0.10 (0.04,0.25) 0.11 0.055 0.10 (0.04,0.25) 
T2 0.09 0.045 0.08 (0.03,0.20) 0.09 0.046 0.08 (0.03,0.20) 
 - - - - 0.14 0.082 0.13 (0.01,0.32) 
resD * 46.8    41.9    
pD 23.0    28.1    
DIC 69.8    70.0    
* compare to 44 data points  
 
Comparing the fit of both these models using the posterior mean of the residual deviance 
indicates that although the random effects models is a better fit to the data, with a posterior 
mean of the residual deviance of 41.9 against 46.8 for the fixed effect model, this is achieved 
at the expense of more parameters. This better fit can also be seen in the leverage plots for the 
fixed and random effects model (Figure 1 and Figure 2), where two extreme points can be 
seen in Figure 1, at either side of zero. These points refer to the two arms of study 14 (Table 
1) but are no longer so extreme in Figure 2. We would suggest careful re-examination of the 
evidence and consideration of issues such as the existence of important covariates. These and 
other issues are covered in TSD3.35 The DIC suggests that there is little to choose between 
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the two models and the fixed effect model may be preferred since it is easier to interpret 
(Table 2). The posterior median of the pooled log odds ratio of beta-blockers compared to 
control in the fixed effect model is -0.26 with 95% Credible Interval (-0.36, -0.16) indicating 
a reduced mortality in the treatment group. The posterior medians of the probability of 
mortality on the control and treatment groups are 0.10 and 0.08, respectively (with credible 
intervals in Table 2). Results for the random effects model are similar. 
 
Figure 1 Blocker example: Plot of leverage versus Bayesian deviance residual wik for each data point, with 
curves of the form x2+y=c, with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the fixed 
effect model.  
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Figure 2 Blocker example: Plot of leverage versus Bayesian deviance residual wik for each data point, with 
curves of the form x2+y=c, with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the 
random effects model. 
The logit model assumes linearity of effects on the logit scale. A number of authors, notably 
Deeks,36 have rightly emphasised the importance of using a scale in which effects are 
additive, as is required by the linear model. Choice of scale can be guided by goodness of fit, 
or by lower between-study heterogeneity, but there is seldom enough data to make this choice 
reliably, and logical considerations (see below) may play a larger role. Quite distinct from 
choice of scale for modelling, is the issue of how to report treatment effects. Thus, while one 
might assume linearity of effects on the logit scale, the investigator, given information on the 
absolute effect of one treatment, is free to derive treatment effects on other scales, such as 
Risk Difference (RD), Relative Risk (RR), or Numbers Needed to Treat (NNT). The 
computer code provided in the Appendix shows how this can be done. An advantage of 
Bayesian MCMC is that appropriate distributions, and therefore credible intervals, are 
automatically generated for all these quantities.   
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3 GENERALISED LINEAR MODELS 
We now extend our treatment to models other than the well-known logit link for data with a 
binomial likelihood. The essential idea is that the basic apparatus of the meta-analysis 
remains the same, but the likelihood and the link function can change to reflect the nature of 
the data (continuous, rate, categorical), and the sampling process that generated it (Normal, 
Poisson, Multinomial, etc). In GLM theory,12 a likelihood is defined in terms of some 
unknown parameters γ (for example a Binomial likelihood as in Section 2), while a link 
function, g(∙), maps the parameters of interest onto the plus/minus infinity range. Our meta-
analysis model for the logit link in equation (3), now becomes a GLM taking the form 
 , { 1}( ) ik i i bk kg I        (5) 
where g is an appropriate link function (for example the logit link), and ik  is the linear 
predictor, usually a continuous measure of the treatment effect in arm k of trial i (for example 
the log-odds). As before, μi are the trial-specific baseline effects in a trial i, treated as 
unrelated nuisance parameters. The δi,bk are the trial-specific treatment effect of the treatment 
in arm k relative to the control treatment in arm b (b=1) in that trial, and  
 2,12 12~ ( , )i N d   (6) 
as in equation (1). 
Table 3 Commonly used link functions and their inverse with reference to which likelihoods they can be 
applied to. 
Link 
Link function 
( )g   
Inverse link function 
1( )g   Likelihood 
Identity  θ Normal 
Logit  ln (1 )   exp( )1 exp( )  Binomial Multinomial 
Log ln( )  exp( )  Poisson 
Complementary log-log 
(cloglog)  ln ln(1 )    1 exp exp( )   
Binomial 
Multinomial 
Reciprocal link 1/   1 /  Gamma 
Probit 1( )  ( )  
Binomial 
Multinomial 
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We now turn to consider the different types of outcome data generated in trials, and the 
GLMs required to analyses them. In each case, the basic model for meta-analysis remains the 
same (equations (5) and (6)). What changes are the likelihood and the link function. In a 
Bayesian framework, we also need to pay careful attention to the specification of the priors 
for the variance parameter. Table 3 has details of the most commonly used likelihoods, link 
and inverse link functions. The formulae for the residual deviance and the predicted values 
needed to calculate pD for all the different likelihoods described are available in Table 4.  
Table 4  Formulae for the residual deviance and model predictors for common likelihoods 
Likelihood 
Model 
prediction Residual Deviance 
~ Binomial( , )ik ik ikr p n  iˆk ik ikr n p  2 log ( ) logˆ ˆ
ik ik ik
ik ik ik
i k ik ik ik
r n rr n r
r n r
    
          
  
~ Poisson( )ik ik ikr E  iˆk ik ikr E   ˆ2 log ˆ
ik
ik ik ik
i k ik
rr r r
r
  
      
  
 2~ ,ik ik iky N y se  
seik assumed known 
iky  
 2
2
ik ik
i k ik
y y
se
 
 
 
 
  
, ,1: , ,1:, ~ Multinomial( , )i k J i k J ikr p n  iˆkj ik ikjr n p  2 log ˆ
ikj
ikj
i k j ikj
r
r
r
  
      
   
Multivariate Normal 
 ,1: ,1: ( )~ ,i k k i k k ky N y Σ  ,1:i k
y  
1
,1: ,1: ,1: ,1:( ) ( )
T
i k i k i k i k
i
y y y y  Σ
 
 
3.1 RATE DATA: POISSON LIKELIHOOD AND LOG LINK 
When the data available for the RCTs included in the meta-analysis is in the form of counts 
over a certain time period (which may be different for each trial), a Poisson likelihood and a 
log link is used. Examples would be the number of deaths, or the number of patients in whom 
a device failed. But, rather than having a denominator number at risk, what is supplied is a 
total number of person-years at risk. For patients who do not reach the end event, the time at 
risk is the same as their follow-up time. For those that do, it is the time from the start of the 
trial to the event: in this way the method allows for censored observations.  
Defining rik as the number of events occurring in arm k of trial i during the trial follow-up 
period, Eik as the exposure time in person-years and λik as the rate at which events occur in 
arm k of trial i, we can write the likelihood as 
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 ~ Poisson( )ik ik ikr E   
The parameter of interest is the hazard, the rate at which the events occur in each trial arm, 
and this is modelled on the log scale. The linear predictor in equation (5) is therefore on the 
log-rate scale: 
 , { 1}log( )ik ik i i bk kI        (7) 
A key assumption of this model is that in each arm of each trial the hazard is constant over 
the follow-up period. This can only be the case in homogeneous populations where all 
patients have the same hazard rate. In populations with constant but heterogeneous rates, the 
average hazard must necessarily decrease over time, as those with higher hazard rates tend to 
reach their end-points earlier and exit from the risk set. 
These models are also useful for certain repeated event data. Examples would be the number 
of accidents, where each individual may have more than one accident. Here one would model 
the total number of accidents in each arm, that is, the average number of accidents multiplied 
by the number of patients. The Poisson model can also be used for observations repeated in 
space rather than time: for example the number of teeth requiring fillings. Using the Poisson 
model for repeated event data makes the additional assumption that the events are 
independent, so that, for example, an accident is no more likely in an individual who has 
already had an accident than in one who has not. Readers may consult previous work37-39 for 
examples. Dietary Fat Examples 2(a) and 2(b) in the Appendix illustrate random and fixed 
effects meta-analyses of this sort.  
 
3.2 RATE DATA: BINOMIAL LIKELIHOOD AND CLOGLOG LINK 
In some meta-analyses, each included trial reports the proportion of patients reaching an end-
point at a specified follow-up time, but the trials do not all have the same follow-up time. 
Defining rik as the number of events in arm k of trial i, with follow-up time fi (measured in 
days, weeks etc), then the likelihood for the data generating process is Binomial, as in 
equation (2). Using a logit model implies one of the following assumptions: that all patients 
who reach the end-point do so by some specific follow-up time, and further follow-up would 
make no difference; or that the proportional odds assumption holds. This assumption implies 
a complex form for the hazard rates.40 If longer follow-up results in more events, the standard 
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logit model is hard to interpret. The simplest way to account for the different length of 
follow-up in each trial, is to assume an underlying Poisson process for each trial arm, with a 
constant event rate ik, so that Tik, the time until an event occurs in arm k of trial i, has an 
exponential distribution  
 ~ ( )ik ikT Exp    
The probability that there are no events by time fi in arm k of trial i, the survival function, can 
be written as 
 Pr( ) exp( )ik i ik iT f f     
Then, for each trial i, pik, the probability of an event in arm k of trial i after follow-up time fi 
can be written as 
 1 Pr( ) 1 exp( )ik ik i ik ip T f f       (8) 
which is time dependent.   
We now model the event rate ik, taking into account the different follow-up times fi. Since 
equation (8) is a non-linear function of log(ik) the complementary log-log (cloglog) link 
function41 (Table 3) is used to obtain a generalised linear model for log(ik) giving 
cloglog( ) log( ) log( )ik ik i ikp f    , and log(ik) is modelled as in equation (7): 
 , { 1}cloglog( ) log( )ik ik i i i bk kp f I         
with the treatment effects ,i bk  representing log-hazard ratios. The Diabetes Example, 
programs 3(a) and 3(b) in the Appendix, illustrates a cloglog meta-analysis. 
The assumptions made in this model are the same as those for the Poisson rate models, 
namely that the hazards are constant over the entire duration of follow-up. This implies 
homogeneity of the hazard across patients in each trial, a strong assumption, as noted above. 
Nonetheless, this assumption may be preferable to assuming that the follow-up time makes 
no difference to the number of events. The clinical plausibility of these assumptions should 
be discussed and supported by citing relevant literature, or by examination of evidence of 
changes in outcome rates over the follow-up period in the included trials. 
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When the constant hazards assumption is not reasonable, but further follow-up time is 
believed to result in more events, extensions are available that allow for time-varying rates. 
One approach is to adopt piece-wise constant hazards. These models can be fitted if there is 
data reported at multiple follow-up times within the same study.42,43 An alternative is to fit a 
Weibull model, which involves an additional “shape” parameter : 
 Pr( ) exp[( ) ]ik i ik iT f f
     
which leads to: 
 , { 1}cloglog( ) (log( ) )ik ik i i i bk kp f I          
Although no longer a GLM, since a non-linear predictor is used, these extensions lead to 
major liberalisation of modelling, but require more data. The additional Weibull parameter, 
for example, can only be adequately identified if there is data on a wide range of follow-up 
times, and if investigators are content to assume the same shape parameter for all treatments. 
 
3.3 COMPETING RISKS: MULTINOMIAL LIKELIHOOD AND LOG LINK 
A competing risk analysis is appropriate where multiple, mutually exclusive end-points have 
been defined, and patients leave the risk set if any one of them is reached. For example, in 
trials of treatments for schizophrenia44 observations continued until patients either relapsed, 
discontinued treatment due to intolerable side effects, or discontinued for other reasons. 
Patients who remain stable to the end of the study are censored. The statistical dependencies 
between the competing outcomes need to be taken into account in the model. These 
dependencies are essentially within-trial, negative correlations between outcomes, applying 
in each arm of each trial. They arise because the occurrence of outcome events is a stochastic 
process, and if more patients should by chance reach one outcome, then fewer must reach the 
others. 
Trials report rikj, the number of patients in arm k of trial i reaching each of the mutually 
exclusive end-points j=1,2,…J, at the end of follow-up in trial i, fi. In this case the responses 
rikj will follow a multinomial distribution: 
 , , 1,..., , , 1,..., , ,
1
~ Multinomial( , )  with  1
J
i k j J i k j J ik i k j
j
r p n p 

  (9) 
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and the parameters of interest are the rates (hazards) at which patients move from their initial 
state to any of the end-points j, ikj. Note that the Jth endpoint represents the censored 
observations, i.e. patients who do not reach any of the other end-points before the end of 
follow-up. 
If we assume constant hazards ikj acting over the period of observation fi in years, weeks etc, 
the probability that outcome j has occurred by the end of the observation period for arm k in 
trial j is: 
 
1
1 1
1
( ) [1 exp( )],       1, 2,3,..., 1Jikjikj i i ikuJ u
ikuu
p f f j J




 

    

  
The probability of remaining in the initial state, that is the probability of being censored, is 
simply 1 minus the sum of the probabilities of arriving at any of the J-1 absorbing states, ie:  
 1
1
( ) 1 ( )JikJ i iku iup f p f


    
The parameters of interest are the hazards, ikj, and these are modelled on the log scale 
 , , { 1}log( )ikj ikj ij i bk j kI         
The trial-specific treatment effects δi,bk,j of the treatment in arm k relative to the control 
treatment in arm b of that trial for outcome j, are assumed to follow a normal distribution  
 2,12, 12~ ( , )i j j jN d    
The between-trials variance of the random effects distribution, 2j , is specific to each 
outcome j. Three models for the variance can be considered: a fixed effect model, where 2j
=0; a Random Effects Single Variance model where the between-trial variance 2j = 2 , 
reflecting the assumption that the between-trials variation is the same for each outcome; and a 
Random Effect Different Variances model where 2j  denotes a different between-trials 
variation for each outcome j. See the Schizophrenia Example 4 in the Appendix for an 
illustration.   
These competing risks models share the same assumptions as the cloglog models presented in 
Section 3.2 to which they are closely related: constant hazards over time, implying 
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proportional hazards, for each outcome. A further assumption is that the ratios of the risks 
attaching to each outcome must also remain constant over time (proportional competing 
risks). Further extensions where the assumptions are relaxed are available.45 
 
3.4 CONTINUOUS DATA: NORMAL LIKELIHOOD AND IDENTITY LINK 
With continuous outcome data the meta-analysis is based on the sample means, yik, with 
standard errors seik. As long as the sample sizes are not too small, the Central Limit Theorem 
allows us to assume that, even in cases where the underlying data are skewed, the sample 
means are approximately normally distributed, so that the likelihood can be written as 
  2~ ,ik ik iky N se   
The parameter of interest is the mean, ik , of this continuous measure which is unconstrained 
on the real line. The identity link is used (Table 3) and the linear model can be written on the 
natural scale as 
 , { 1}ik i i bk kI      (10) 
See the Parkinson’s Example, programs 5(a) and 5(b) in the Appendix, for WinBUGS code.  
3.4.1 Before/after studies: change from baseline measures 
In cases where the original trial outcome is continuous and measured at baseline and at a pre-
specified follow-up point the most common method is to base the meta-analysis on the mean 
change from baseline for each patient and an appropriate measure of uncertainty (e.g. the 
variance or standard error) which takes into account any within-patient correlation. It should 
be noted that the most efficient and least biased statistic to use is the mean of the final 
reading, having adjusted for baseline via regression/ANCOVA. Although this is seldom 
reported, when available these should be the preferred outcome measures.5  
The likelihood for the mean change from baseline in arm k of trial i, iky , with change 
variance ikV
  can be assumed normal such that 
  ~ ,ik ik iky N V    
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The parameter of interest is the mean, ik , of this continuous measure which is unconstrained 
on the real line. The identity link is used (Table 3) and the linear model can be written on the 
natural scale as in equation (10). 
However, in practice many studies fail to report an adequate measure of the uncertainty for 
the before-after difference in outcome and instead report the mean and variance, ( )biky  and 
( )b
ikV , (or other measure of uncertainty) at baseline (before), and at follow-up times (after), 
( )a
iky  and 
( )a
ikV , separately. While the mean change from baseline can be easily calculated as  
 ( ) ( )b aik ik iky y y
     
to calculate ikV
  for such trials, information on the within-patient correlation ρ is required 
since 
 ( ) ( ) ( ) ( )2b a b aik ik ik ik ikV V V V V
       
Information on the correlation ρ is seldom available. It may be possible to obtain information 
from a review of similar trials using the same outcome measures, or else a reasonable value 
for ρ, often 0.5 (which is considered conservative) or 0.7,46 can be used alongside sensitivity 
analyses.5,47 A more sophisticated approach, which takes into account the uncertainty in the 
correlation, is to use whatever information is available within the dataset, from trials that 
report both the before/after variances and the change variance (see Section 4), and possibly 
external trials as well, to obtain an evidence-based prior distribution for the correlation, or 
even to estimate the correlation and the treatment effect simultaneously within the same 
analysis.48  
 
3.5 TREATMENT DIFFERENCES 
Trial results are sometimes only available as overall, trial-based summary measures, for 
example as mean differences between treatments, log-odds ratios, log-risk ratios, log-hazard 
ratios, risk differences, or some other trial summary statistic and its sample variance. In this 
case we can assume a normal distribution for the continuous measure of treatment effect of 
arm k relative to arm 1 in trial i, iky , with variance ikV , such that  
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  ~ ,ik ik iky N V   
The parameters of interest are the trial-specific mean treatment effects ik . An identity link is 
used and since no trial-specific effects of the baseline or control treatment can be estimated 
the linear predictor is reduced to ,ik i bk  . The trial baselines are eliminated and the ,i bk  
are, exactly as in all previous models, assumed to come from a random effects distribution 
2
,12 12~ ( , )i N d   or to be fixed ,12 12i d  . Examples 7 (Parkinson’s Differences) in the 
Appendix can be consulted. 
Readers will recognise that this is overwhelmingly the most common form of meta-analysis, 
especially amongst the Frequentist methods. The case where the yik are log-odds ratios, and 
an inverse-variance weighting is applied, with variance based on the normal theory 
approximation, remains a main-stay in applied meta-analytic studies. We refer to some of the 
key literature comparing different meta-analytic estimators and methods in the discussion. 
An important caveat about synthesis based on treatment differences relates to multi-arm 
trials. In Section 5 we show how the framework developed so far applies to syntheses that 
include multi-arm trials. However, trial-level data based on treatment differences present 
some special problems because, unlike data aggregated at the arm-level, there are correlations 
between the treatment differences that require adjustment to the likelihood. Details are given 
in Section 5.1. The WinBUGS coding we provide (Example 7) incorporates these 
adjustments. This point is also taken up in our discussion of alternative software (Section 7).  
3.5.1 Standardised mean differences 
There are a series of standardised mean difference (SMD) measures commonly used with 
psychological or neurological outcome measures. These can be synthesised in exactly the 
same way as any other treatment effect summary. We include some specific comments here 
relating to the special issues they raise.  
The main role of the SMD is to facilitate combining results from trials which have reported 
outcomes measured on different continuous scales. For example, some trials might use the 
Hamilton Depression scale, others the Montgomery-Asberg Depression Rating Scale. The 
idea is that the two scales are measuring essentially the same quantity, and that results can be 
placed on a common scale if the mean difference between the two arms in each trial is 
divided by its standard deviation. The best known SMD measures are Cohen’s d49, and 
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Hedges’ adjusted g,50 which differ only in how the pooled standard deviation is defined and 
the fact that Hedges’ g is adjusted for small sample bias: 
 
2 2
1 1 2 2
1 2
difference in meansCohen's d =
( 1) ( 1)n s n s
n n
  

  
 
2 2
1 21 1 2 2
1 2
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4( ) 9( 1) ( 1)
2
n nn s n s
n n
 
       
 
 (11) 
where n1 and n2 represent the sample sizes and s1 and s2 the standard errors of the means in 
arms 1 and 2 of a given trial. 
However, dividing estimates through by the sample standard deviation introduces additional 
heterogeneity in two ways. First, standard deviations are themselves subject to sampling 
error, and secondly, the use of SMD opens the results to various kinds of distortion because 
trials vary in how narrowly defined the patient population is. For example we would expect 
trials with narrow inclusion criteria such as “severe depression”, to have smaller sample 
standard deviations, and thus larger SMDs, than trials on patients with “severe to moderate 
depression”. A procedure that would produce more interpretable results would be to divide all 
estimates from a given test instrument by the standard deviation obtained in a representative 
population sample, external to the trial.   
The Cochrane Collaboration recommends the use of Hedges’ g (equation (11)), while noting 
that interpretation of the overall intervention effect is difficult.5 It recommends re-expressing 
the pooled SMD in terms of effect sizes as small, medium or large (according to some rules 
of thumb), transforming the pooled SMD into an Odds Ratio, or re-expressing the SMD in 
the units of one or more of the original measurement instruments,5 although it is conceded 
none of these manoeuvres mitigates the drawbacks mentioned above. 
SMDs are sometimes used for non-continuous outcomes. For example in a review of topical 
fluoride therapies to reduce caries in children and adolescents, the outcomes were the number 
of new caries observed but the mean number of caries in each trial arm were modelled as 
SMD.51 Where possible, it is preferable to use the appropriate GLM, in this case a Poisson 
likelihood and log link, as this is likely to reduce heterogeneity.38 
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3.6 ORDERED CATEGORICAL DATA: MULTINOMIAL LIKELIHOOD AND PROBIT 
LINK 
In some applications, the data generated by the trial may be continuous but the outcome 
measure categorised, using one or more pre-defined cut-offs. Examples include the PASI 
(Psoriasis Area Severity Index) and the ACR (American College of Rheumatology) scales, 
where it is common to report the percentage of patients who have improved by more than 
certain benchmark relative amounts. Thus ACR-20 would represent the proportion of patients 
who have improved by at least 20% on the ACR scale, PASI-75 the proportion who have 
improved by at least 75% on the PASI scale. Trials may report ACR-20, ACR-50 and ACR-
70, or only one or two of these end-points. We can provide a coherent model and make 
efficient use of such data by assuming that the treatment effect is the same regardless of the 
cut-off. This assumption can be checked informally by examining the relative treatment 
effects at different cut-offs in each trial and seeing if they are approximately the same. In 
particular, there should not be a systematic relationship between the relative effects at 
different cut-off points. The residual deviance check of model fit is also a useful guide. 
The likelihood is the same as in the competing risk analysis: trials report rikj, the number of 
patients in arm k of trial i belonging to different, mutually exclusive categories j=1,2,…J, 
where these categories represent the different thresholds (e.g. 20%, 50% or 70% 
improvement), on a common underlying continuous scale. The responses for each arm k of 
trial i in category j will follow a multinomial distribution as defined in equation (9) and the 
parameters of interest are the probabilities, pikj, that a patient in arm k of trial i belongs to 
category j. We may use the probit link function to map pikj onto the real line. This is the 
inverse of the normal cumulative distribution function  (see Table 3). The model can be 
written as 
 1 , { 1}( )ikj ikj ij i bk kp I  

      
or equivalently 
 , { 1}( )ikj ij i bk kp I       
In this setup, the pooled effect of taking the experimental treatment instead of the control is to 
change the probit score (or Z score) of the control arm, by δi,bk standard deviations. This can 
be translated back into probabilities of events by noting that when the pooled treatment effect 
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12 0d  , then for a patient population with an underlying probability πj of an event in 
category j, the experimental treatment will increase this probability to  1 12( )j d   .  
The model is set-up with the assumption that there is an underlying continuous variable 
which has been categorised by specifying different cut-offs, zij, which correspond to the point 
at which an individual moves from one category to the next in trial i. Several options are 
available regarding the relationship between outcomes within each arm. Re-writing the model 
as 
 , { 1}( )ikj i ij i bk kp z I        
we can consider the terms zij as the differences on the standard normal scale between the 
response to category j and the response to category j-1 in all the arms of trial i. One option is 
to assume a ‘fixed effect’ zij =zj for each of the J-1 categories over all trials i, or a ‘random 
effect’ in which the trial-specific terms are drawn from a distribution, but are the same for 
each arm within a trial, taking care to ensure that the zj are increasing with category (i.e. are 
ordered). Choice of model can be made on the basis of DIC. 
Example 6 (Psoriasis) in the Appendix, illustrates fixed and random effects meta-analyses 
with fixed effects zj. Examples of very similar analyses can be found in the health technology 
assessment literature on psoriasis,52 psoriatic arthritis53 and rheumatoid arthritis,54 although in 
some cases random effect models were placed on baselines, which is not the practice we 
recommend. The model, and the WinBUGS coding, are appropriate in cases where different 
trials use different thresholds, or when different trials report different numbers of thresholds, 
as is the case in the Psoriasis Example 6. There is, in fact, no particular requirement for trials 
to even use the same underlying scale, in this case the PASI: this could however require an 
expansion of the number of categories. 
Unless the response probabilities are very extreme the probit model will be undistinguishable 
from the logit model in terms of model fit or DIC. Choosing which link function to use 
should therefore be based on the data generating process and on the interpretability of the 
results.   
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3.7 ADDITIVE AND MULTIPLICATIVE EFFECTS WITH BINOMIAL DATA, AND 
OTHER NON-CANONICAL LINKS 
It was mentioned earlier (Section 2.1) that the appropriate scale of measurement, and thus the 
appropriate link function, was the one in which effects were linear. It is common to see Log 
Relative Risks (LRR) and Risk Differences (RD) modelled using the treatment difference 
approach (Section 3.4), but there are advantages to adopting an arm-based analysis with 
Binomial likelihoods (see discussion). To perform an arm-based analysis using the RD or 
LRR requires special programming, because, unlike the “canonical”12 logit models, there is 
otherwise nothing to prevent the fitted probabilities in a risk difference or log risk model 
from being outside the natural zero-to-one range for probabilities. Suitable adjustments to 
coding have been published for Frequentist software,{Wacholder, 1986 84 /id} or more 
recently for WinBUGS.56 A Risk Difference model would be: 
 
, { 1}
~ (0,1)
min(max( , ), (1 ))
i
ik i i bk i i k
Uniform
p I

       
  
The effect of this construction is to guarantee that both the baseline probability i  and 
,i i bk   remain in the interval (0,1) with δi,bk interpreted as a Risk Difference. For a Relative 
Risk model: 
 
, { 1}
exp( ) ~ (0,1)
log( ) min( , )
i
ik i i bk i k
Uniform
p I

     
  
Here, δi,bk is a Log Relative Risk. Warn et al.56 should be consulted for further details of the 
WinBUGS coding and considerations on prior distributions.  
Our experience with these models is that they can sometimes be less stable, and issues of 
convergence and starting values need especially close attention. One can readily avoid their 
use, of course, by using estimates of Relative Risk or Risk Difference as data. But this 
approach runs into difficulties when multi-arm trials are included (see Sections 5.1 and 7). 
 
4 SHARED PARAMETER MODELS 
Shared parameter models allow the user to generate a single coherent synthesis when trials 
report results in different formats. For example some trials may report binomial data for each 
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arm, while others report only the estimated log odds ratios and their variances; or some may 
report numbers of events and time at risk, while others give binomial data at given follow-up 
times. In either case the trial-specific relative effects δi,bk represent the shared parameters, 
which are generated from a common distribution regardless of which format trial i is reported 
in.  
So if in a meta-analysis of M trials, M1 trials report the mean of a continuous outcome for 
each arm of the trial, and the remaining trials report only the difference in the means of each 
experimental arm relative to control, a shared parameter model to obtain a single pooled 
estimate, can be written as a combination of the models presented in Section 3.4 such that 
  2~ ,ik ik iky N se  
where 
 , { 1} 1
, 1
for 1,..., ; 1, 2,...,
for 1,..., ; 2,...,
i i bk k i
ik
i bk i
I i M k a
i M M k a
 


      
  
and ai represents the number of arms in trial i (ai=2,3,…). The trial-specific treatment effects 
δi,bk come from a common random effects distribution 2,12 12~ ( , )i N d   as before. 
Separate likelihood statements could also be defined, so for example in a meta-analysis with 
a binomial outcome, the M1 trials reporting the binomial counts in each trial arm could be 
combined with the trials reporting only the log-odds ratio of each experimental treatment 
relative to control and its variance. In this case the binomial data would be modelled as in 
Section 2.1 and the continuous log-odds ratio data could be modelled as in Section 3.5, with 
the shared parameter being the trial-specific treatment effects δi,bk as before. For a fixed effect 
model, δi,12 can be replaced by d12 in the model specification. 
These models can be easily coded in WinBUGS by having different loops for each of the data 
types, taking care to index the trial-specific treatment effects appropriately. 
Examples of shared parameter models will primarily include cases where some trials report 
results for each arm, whether proportions, rates, or continuous outcomes, and other trials 
report only the between-arm differences. A common model for log rates could be shared 
between trials with Poisson outcomes and time-at-risk and trials with Binomial data with a 
cloglog link; log rate ratios with identity link and normal approximation sample variance 
could form a third type of data for a shared log rate model. These models can be used to 
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combine studies reporting outcomes as mean differences or as binomial data57 and to 
combine data on survival endpoints which have been summarised either by using a hazard 
ratio or as number of events out of the total number of patients.58 Another possibility would 
be to combine trials reporting test results at one or more cut-points using a probit link with 
binomial or multinomial likelihoods, with data on continuous outcomes transformed to a 
standard normal deviate scale.   
To combine trials which report continuous outcome measures on different scales with trials 
reporting binary outcomes created by dichotomising the underlying continuous scale, authors 
have suggested converting the odds ratios calculated from the dichotomous response into a 
SMD,5,59 or converting both the binary and continuous measures into log-odds ratios for 
pooling.60 These methods could be used within a shared parameter model. 
Examples 7 and 8 (Parkinson’s differences and shared parameter) in the Appendix are shared 
parameter models.  
 
5 EXTENSION TO INDIRECT COMPARISONS AND NETWORK 
META-ANALYSIS 
In Section 2 we defined a set of M trials over which the study-specific treatment effects of 
treatment 2 compared to treatment 1, δi,12, were exchangeable with mean d12 and variance 
2
12 . We now suppose that, within the same set of trials (i.e. trials which are relevant to the 
same research question), comparisons of treatments 1 and 3 are also made. To carry out a 
pairwise random effects meta-analysis of treatment 1 v 3, we would now assume that the 
study-specific treatment effects of treatment 3 compared to treatment 1, δi,13, are also 
exchangeable such that  2,13 13 13~ ,i N d  . If so, it can then be shown that the study-specific 
treatment effects of treatment 3 compared to 2, δi,23, are also exchangeable: 
  2,23 23 23~ ,i N d    
This follows from the transitivity relation ,23 ,13 ,12i i i    . It can further be shown
61 that this 
implies  
 23 13 12d d d   (12) 
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and 
 2 2 2 (1)23 12 13 23 12 132          
where (1)23  represents the correlation between the relative effects of treatment 3 compared to 
treatment 1, and the relative effect of treatment 2 compared to treatment 1 within a trial (see 
Lu & Ades61). For simplicity we will assume equal variances in all subsequent methods, i.e. 
2 2 2 2
12 13 23      , and this implies that the correlation between any two treatment 
contrasts in a multi-arm trial is 0.5.19 For heterogeneous variance models see Lu & Ades.61 
The exchangeability assumptions regarding the treatment effects ,12i  and ,13i therefore make 
it possible to derive indirect comparisons of treatment 3 vs treatment 2, from trials of 
treatment 1 vs 2 and 1 vs 3, and also allow us to include trials of treatments 2 vs 3 in a 
coherent synthesis with the 1 vs 2 and 1 vs 3 trials.  
Note the relationship between the standard assumptions of pair-wise meta-analysis, and those 
required for indirect and mixed treatment comparisons. For a random effects pair-wise meta-
analysis, we need to assume exchangeability of the effects ,12i  over the 1 vs 2 trials, and also 
exchangeability of the effects ,13i  over the 1 vs 3 trials. For network meta-analysis, we must 
assume the exchangeability of both treatment effects over both 1 vs 2 and 1 vs 3 trials. The 
theory extends readily to additional treatments k = 4,5…,S. In each case we must assume the 
exchangeability of the δ’s across the entire set of trials. Then the within-trial transitivity 
relation is enough to imply the exchangeability of all the treatment effects ,i xy . The 
consistency equations21 
 
23 13 12
24 14 12
( 1), 1 1,( 1)
  
  
s s s s
d d d
d d d
d d d 
 
 
 
  
are also therefore implied; they are assumptions required by indirect comparisons and MTC, 
but, given that we are assuming that all trials are relevant to the same research question, they 
are not additional assumptions. However, whilst in theory, consistency of the treatment 
effects must hold, there may be inconsistency in the evidence. Methods to assess evidence 
consistency are addressed in TSD4.28 The consistency equations can also be seen as an 
example of the distinction between the (s-1) basic parameters62 d12, d13, d14, …, d1s on which 
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prior distributions are placed, and the functional parameters which are functions of the basic 
parameters, and represent the remaining contrasts. It is precisely the reduction in the number 
of dimensions, from the number of functions on which there are data to the number of basic 
parameters, that allows all data, whether directly informing basic or functional parameters, to 
be combined within a coherent (internally consistent) model.  
Now that several treatments are being compared, we clarify our notation a little, and have the 
trial-specific treatment effects of the treatment in arm k, relative to the control treatment (in 
arm 1), drawn from a common random effects distribution: 
 
1
2
,1 ,~ ( , )i iki k t tN d    
where 
1 ,i ikt t
d  represents the mean effect of the treatment in arm k in trial i, tik, compared to the 
treatment in arm 1 of trial i, ti1, and 2 represents the between-trial variability in treatment 
effects (heterogeneity). For trials that compare treatments 1 and 2 
1 , 12i ikt t
d d , for trials that 
compare treatments 2 and 3 
1 , 23i ikt t
d d  and so on. The pooled treatment effect of treatment 3 
compared to treatment 2, d23, is then obtained from equation (12). 
The WinBUGS code provided in the Appendix will extend to MTC. Examples 3 to 8 in the 
Appendix illustrate analyses with multiple treatments. 
 
5.1 INCORPORATING MULTI-ARM TRIALS 
Suppose we have a number of multi-arm trials involving the treatments of interest, 1,2,3,4,… 
Among commonly suggested stratagems are combining all active arms into one, or splitting 
the control group between all relevant experimental groups, or ignoring all but two of the trial 
arms.5 None of these are satisfactory. The question of how to conduct a meta-analysis of the 
multi-arms trials has been considered in a Bayesian framework by Lu & Ades,20 and in a 
frequentist framework by Lumley22 and Chootrakool & Shi.63   
Based on the same exchangeability assumptions above, a single multi-arm trial will estimate 
a vector of random effects iδ . For example a three-arm trial will produce two random effects 
and a four-arm trial three. Assuming, as before, that the relative effects all have the same 
between-trial variance we have 
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 (13) 
where iδ  is the vector of random effects, which follows a multivariate normal distribution, ai 
represents the number of arms in trial i (ai=2,3,…) and 
1 11, 1,i ik ik it t t t
d d d  . Then the 
conditional univariate distributions for the random effect of arm k>2, given all arms from 2 to 
k-1, is (see eg. Raiffa & Schlaiffer64) 
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 (14) 
Either the multivariate distribution in equation (13) or the conditional distributions in 
equation (14) must be used to estimate the random effects for each multi-arm study so that 
the between-arm correlations between parameters are taken into account. The code presented 
in the Appendix uses the formulation in equation (14) as it allows for a more generic code 
which works for trials with any number of arms. 
This formulation provides another interpretation of the exchangeability assumptions made in 
the previous section, and indeed another way of deducing the consistency relations. This is 
that we may consider a connected network of M trials involving S treatments to originate 
from M S-arm trials, but that some of the arms are missing at random (MAR). (Note that 
MAR does not mean that the choice of arms is random, but that the missingness of arms is 
unrelated to the efficacy of the treatment). It should be noted that the general formulation is 
no different from the model presented by Higgins & Whitehead.19 
The WinBUGS code provided in the Appendix is based on a conditional distribution 
formulation of the multivariate normal distribution. It therefore exactly instantiates the theory 
behind network meta-analysis that relates it to pair-wise meta-analysis. The code in the 
Appendix will analyse pair-wise meta-analysis, indirect comparisons, network meta-analysis 
(MTC) and multi-arm trials without distinction. 
5.1.1 Multi-arm trials with treatment differences (trial-based summaries) 
As mentioned in Section 3.5, when results from multi-arm trials are presented as (continuous) 
treatment differences relative to the control arm (arm 1), a correlation between the treatment 
37 
 
differences is induced, since all differences are taken relative to the same control arm. Unlike 
the correlations between the relative effect parameters, this correlation is inherent in the data, 
and so requires an adjustment to the likelihood. A trial with ai arms produces ai-1 treatment 
differences which are correlated. The covariance between differences taken with respect to 
the same control arm is equal to the observed variance for the common control arm. So for 
example in a three arm trial comparing treatments A, B and C, letting yAB and yAC represent 
the treatment differences of treatments B and C relative to treatment A, we know that  
 ( ) ( ) ( ) 2 ( , )AB AC AB AC AB ACVar y y Var y Var y Cov y y     (15) 
and,  
 
( ) ( ) ( )
( ) ( ) ( )
AB A B
AC A C
Var y Var y Var y
Var y Var y Var y
 
 
 (16) 
with, yA, yB and yC representing the original measurements on each arm of the trial, because, 
in a randomised controlled trial the measurements in each trial arm are independent. By 
successive replacement of the expressions in equation (16) into equation (15), we have: 
 ( , ) ( )AB AC ACov y y Var y   
So, the likelihood for a trial i with ai arms would be defined as multivariate normal 
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where the diagonal elements in the variance-covariance matrix represent the variances of the 
treatment differences and the off-diagonal elements represent the observed variance in the 
control arm in trial i, denoted by 21ise  (see Section 3.4). For example, when the treatment 
differences are given as log-odds ratios, 21ise  is the variance of the log-odds for arm 1 of trial 
i. Example 7 (Parkinson’s Difference) in the Appendix includes a three-arm trial in a meta-
analysis of treatment differences where the variance of the common arm, 21ise , is known. 
When 21ise  is not reported, an approximation should be made, perhaps based on the variances 
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of the differences.58 If the value of the control variance is available only for some of the 
included trials, that information can be used to estimate the parameters of a distribution for 
the control variance (assumed to be common). This estimated distribution can then be used to 
predict the variance of the control arm, in the trials where it is missing. This method has been 
used, in a slightly different context, to predict missing variances.65 Riley66 provides a review 
of methods to impute unknown within-study correlations within the context of multivariate 
meta-analysis. These methods can also be applied to network meta-analysis with multi-arm 
trials.  
 
6 TECHNICAL ISSUES IN BAYESIAN MCMC 
The use of the WinBUGS Bayesian MCMC software has advantages (Section 7), but it also 
requires some care. Users are strongly advised to acquire a good understanding of Bayesian 
theory,67 and to follow advice given in the WinBUGS manual. Particular care must be taken 
in checking convergence, and we suggest that at least three chains are run, starting from 
widely different (yet sensible) initial values. The diagnostics recommended in the literature 
should be used to check convergence.68,69 Users should also ensure that, after convergence, 
each chain is sampling from the same posterior. Posteriors should be examined visually for 
spikes and unwanted peculiarities, and both the initial “burn-in” and the posterior samples 
should be conservatively large. The number of iterations for both must be reported in the 
analysis. An often cited guideline suggests that the Monte Carlo error, which reflects both the 
number of simulations and the degree of autocorrelation, should be no more than 5% of the 
posterior standard deviation of the parameters of interest. 
Beyond these warnings, which apply to all Bayesian MCMC analyses, evidence synthesis 
models have particular properties which may require careful examination: choice of reference 
treatment, choice of prior distributions and zero counts in binomial and Poisson data. 
 
6.1 CHOICE OF REFERENCE TREATMENT 
While the likelihood is not altered by a change in which treatment is taken to be “Treatment 
1”, the choice of the reference treatment can affect the posterior estimates because priors 
cannot be totally non-informative. However, for the vague priors we suggest throughout for μi 
and d1k (see below) we expect the effect to be negligible. Choice should therefore be based on 
ease of interpretation, with placebo or standard treatment usually taken as Treatment 1. In 
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larger networks, it is preferable to choose as Treatment 1 a treatment that is in the “centre” of 
the network. In other words, choose the treatment that has been trialled against the highest 
number of other treatments. The purpose of this is to reduce strong correlations that may 
otherwise be induced between mean treatment effects for each pair of treatments k and h, d1k 
and d1h: these can slow convergence and make for inefficient sampling from the posterior.  
 
6.2 CHOICE OF PRIORS 
We recommend vague or flat priors, such as N(0, 1002), throughout for μi and d1k. 
Informative priors for relative effect measures would require special justification. 
It has become standard practice to also set vague priors for the between-trial variances. For 
binomial with logit links models, the usual practice is to place a Uniform prior on the 
standard deviation, for example σ ~ Uniform(0,2). The upper limit of 2 represents a huge 
range of trial-specific treatment effects. For example if the median treatment effect was an 
odds ratio of 1.5, then we would expect 95% of trials to have true odds ratios between 0.2 
and 11. For rate models, whether with log or cloglog linking functions, uniform priors on  
may also be used, but investigators need to be aware of the scale: a prior that is vague for a 
rate per year may not be so vague for a rate per month. Similarly, for continuous outcomes 
close attention to the scale of measurement is essential. For trials with blood pressure as the 
outcome σ ~ Uniform(0,100) may be considered vague. The posterior distribution of σ should 
always be inspected to ensure that it is sufficiently different from the prior as this would 
otherwise indicate that the prior is dominating the data and no posterior updating has taken 
place. 
An alternative approach, which was once popular but has since fallen out of favour, is to set a 
vague Gamma prior on the precision, for example 1/2 ~ Gamma(.001,.001). This approach 
gives a low prior weight to unfeasibly large σ on the logit scale. The disadvantage is that this 
puts more weight on values of  near zero. On the other hand, there are occasions where it 
may be an advantage that this prior rules out values of   at zero, because it is not 
uncommon, particularly when data is sparse, that MCMC sampling can “get stuck” at  = 0, 
leading to spikes in the posterior distribution of both   and the treatment effect parameters 
d1k . In these cases a Gamma prior may improve numerical stability and speed convergence.  
However they are formulated, there are major disadvantages in routinely using vague priors, 
although this has become a widely accepted practice. In the absence of large numbers of large 
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trials, the posterior distribution of   will be poorly identified and likely to include values 
that, on reflection, are implausibly high or possibly implausibly low. Two further alternatives 
may be found useful when there is insufficient data to adequately estimate the between-trials 
variation. The first is the use of external data.19 If there is insufficient data in the meta-
analysis, it may be reasonable to use an estimate for  from a larger meta-analysis on the 
same trial outcome involving a similar treatment for the same condition. The posterior 
distribution, or a posterior predictive distribution, from such an analysis could be used to 
approximate an informative prior. The derivation of suitable priors from large numbers of 
meta-analyses is currently being actively researched.  
If there is no data on similar treatments and outcomes that can be used, an informative prior 
can be elicited from a clinician who knows the field. This can be done by posing the question 
in this way. “Suppose we accept that different trials, even if infinitely large, can produce 
different effect sizes. If the average effect was an odds ratio of 1.8 (choose a plausible 
average), what do you think an extremely high and an extremely low effect would be, in a 
very large trial?” Based on the answer to this it should be possible, by trial and error, to 
construct an informative Gamma prior for 1/2, or a Normal prior for  , subject to  > 0. For 
further discussion of priors for variance parameters see Lambert et al.70 and Spiegelhalter et 
al.67 
 
6.3 ZERO CELLS 
Because Binomial and Poisson likelihoods with zero cells are allowed, special precautions do 
not usually need to be taken in the case of the occasional trial with a zero cell count. This is a 
major strength of the Bayesian MCMC approach, because some popular frequentist 
approaches for log odds ratios or log relative risks have to add an arbitrary constant, usually 
0.5, to cells in order to obtain non-infinite estimates of treatment effects and non-infinite 
variance, but in so doing they generate biased estimates of effect size.71,72  
However, in extreme cases where several trials have zero cells and many of the trials are 
small, the models we have recommended can be numerically unstable, either failing to 
converge, or converging to a posterior with very high standard deviation on some of the 
treatment effects. This is unlikely to happen with fixed effect models, and it can often be 
remedied in random effects models by using a (more) informative prior on the variance 
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parameter. A last resort, recognising the assumptions being made, is to put a random effect 
model on the treatment baselines i as well as the relative treatment effects d1k. 
A specific problem arises in sparse networks, in which for example there is only one trial 
making the comparison X vs Y, and treatment Y only appears in this one trial. If the trial 
contains a zero cell, it may not be possible to estimate a treatment effect. One solution is to 
revert to the practice of adding 1 to the denominator and 0.5 to the numerator, or the 0.5 can 
be replaced with a fraction that is closer to the expected treatment effect to reduce bias.72 The 
problem can also be solved by placing a distribution on the baseline model. Trials with zero 
cells in both arms do not contribute evidence in the treatment effect and can be excluded, 
unless a model has been assumed for the baselines (see TSD529).  
Readers should be aware that, when evaluating model fit using the residual deviance, this will 
always appear large (i.e. >1) for individual data points where there are zero cells. This is 
because none of the models presented can actually predict a zero cell since probabilities at 
zero or one are ruled out. Also no leverage can be calculated for these points. 
 
7 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES 
In this section we briefly review the advantages of the Bayesian MCMC approach to 
synthesis for probabilistic decision modelling. Bayesian methods are clearly convenient in 
this context, but frequentist analyses can be used to approximate Bayesian posterior 
sampling, as we describe below. We then provide some pointers to the literature that 
examines the statistical properties of alternative Bayesian and frequentist meta-analytic 
estimators. Finally, we describe frequentist software that can be used for evidence synthesis. 
The statistical reliability of the different synthesis methods is, of course, an entirely separate 
issue from the accuracy of different computational approaches to implementing the synthesis 
method. 
 
7.1 BAYESIAN VERSUS FREQUENTIST APPROACHES IN THE CONTEXT OF 
DECISION MAKING 
One of the advantages of the Bayesian MCMC approach is that sampling from the posterior 
distribution fulfils at the same time the need for posterior inference and the MC approach to 
probabilistic modelling. Although inference in the form of significance tests and interval 
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estimation tends to be set aside when a decision maker follows the rules of cost effectiveness 
analysis (CEA),73 conclusions from CEA may be highly sensitive to the model that is 
assumed from the data. Statistical model critique and model choice are, therefore critical to 
CEA, whether conducted in a Bayesian or frequentist framework. 
Posterior sampling in addition retains the correlation between parameters that is induced by 
their joint estimation from the same data. For this reason, when there are closed loops in the 
evidence structure, it is essential to either use the posterior samples from WinBUGS in the 
decision model or to take steps to propagate the correlations through the model (see below). 
Distributions based on the posterior marginal summaries are not adequate. 
Perfectly valid evidence synthesis is also, of course, produced by frequentist software (see 
below), and the question then arises of how the results from such analyses can be used in a 
probabilistic decision modelling context. For pair-wise meta-analysis and indirect 
comparisons, as long as they are restricted to two-arm trials, and do not involve covariates on 
baselines or treatment effects, it is simple to use the maximum likelihood (ML) estimates and 
their standard errors to create parameter distributions for forward MC sampling. Where 
multi-arm trials or MTC evidence structures (in other words where there are loops in the 
evidence structure), or baseline models, or covariates are involved, two approaches are 
possible. One is the bootstrap,74 which requires re-sampling from the data, and the other is to 
use the ML parameter estimates of all the parameters and their covariance matrix to form a 
multivariate normal distribution from which to carry out MC sampling. The latter is 
technically easier, and the bootstrap runs into difficulties when there are zero cells. This 
multivariate distribution obtained should be approximately the same as a Bayesian posterior 
distribution.   
 
7.2. COMPARISON OF META-ANALYTIC METHODS 
While there is no technical reason why frequentist methods cannot be used, there are a wide 
variety of estimators to choose between for count data, which in specific circumstances can 
produce different results. There is a useful literature comparing meta-analytic estimators for 
binomial data, based on simulation studies. Bradburn et al71 discuss the biases arising from 
the common practice of adding 0.5, or other amounts, to zero cells, and it is an undoubted 
advantage of methods using exact binomial and Poisson likelihoods, like Bayesian MCMC, 
that these problems are very largely avoided (though see Section 6.3). Simulation studies on 
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fixed effect estimators72 have shown that Bayesian MCMC has performed well, and ranks 
with Mantel Haenszel75 and Exact method76 estimators, and is superior to the Peto method77 
and inverse-variance weighting in a wide range of situations. There is a useful simulation 
study of tests of heterogeneity for binomial data.78 
There has, however, been little work comparing Bayesian and non-Bayesian approaches in 
the context of random effect models, nor on our proposal that a choice can be made between 
random and fixed effect models on the basis of the DIC statistics. 
It should be emphasised that except for the Exact method (which only applies to fixed effects 
models), none of the frequentist methods use the Binomial, Multinomial or Poisson 
likelihoods, but instead rely on normal approximations. This should not create problems as 
long as low cells counts are rare.  
Furthermore, in random effects models, the MCMC implementation automatically takes into 
account the uncertainty in the between-study heterogeneity parameter 2. Whilst this is also 
possible using frequentist approaches,79,80 it is rarely done in practice, possibly because such 
models are not currently implemented in user-friendly frequentist software. 
 
7.3. COMPARISON OF EVIDENCE SYNTHESIS SOFTWARE 
In this section we provide a brief review of frequentist software for evidence synthesis, and 
where possible a comparison with the Bayesian MCMC WinBUGS software. We will refer to 
existing literature where possible. Alternative software for pair-wise meta-analysis has been 
developed over the past two decades, both as stand-alone applications and as ‘macro’ routines 
for pre-existing packages. Probably the most comprehensive and up-to-date routines for 
existing software are those developed and freely distributed for STATA81 and R.82 Stand 
alone packages include Comprehensive Meta-Analysis,83 Meta-Analyst84 and MIX85 as well 
as the Cochrane Collaboration software RevMan.86 If pair-wise meta-analysis is all that is 
required, and appropriate estimators are used, this software is perfectly adequate to produce 
estimates and corresponding standard errors to inform a distribution in a probabilistic 
decision model. 
These approaches can also be used to carry out two pairwise meta-analyses from which an 
“indirect” comparison can be formed. This is effectively an implementation of the Bucher 
method for indirect comparisons87 (and a simple example of an MTC network). Note that in a 
random effects context, this approach allows for separate and unrelated meta-analyses for AB 
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and AC whereas all models considered in this guide (and software examples in the Appendix) 
have considered a common random effect. (Note that this could also be achieved in any 
simulation package, including WinBUGS, by setting up distributions for the AB and AC 
effects, and then subtracting one from the other to form a distribution for the BC effect).  
It would appear no stand-alone software to fit MTC models to arbitrarily complex networks 
exists. Perhaps the most general code for frequentist software is that developed by Lumley.22 
However, this fits a different model from the one described in this paper which does not 
assume consistency of direct and indirect evidence and will be discussed in TSD4.28 
It is also important to note that most frequentist software for MTC is based on data on trial-
level differences, and not data aggregated at arm-level. As we saw in Section 5.1, when 
multi-arm trials are involved, it is essential to take account of both the correlation in 
parameters in random effect models, but also the correlations in the likelihood, which affect 
both fixed and random effect models. To the best of our knowledge, there is only one 
frequentist software module available for STATA, mvmeta, that takes account of the 
correlations at the data level.81,88 Frequentist analysis can also be correctly carried out in 
SAS.89 In our experience, failure to make the adjustment can give materially different results 
whenever multi-arm trials form a substantial proportion of the evidence for any treatment 
contrast.  
 
8. FURTHER READING 
This brief introduction raises many further questions. Some of these are taken up in detail in 
the other technical guides in this series. TSD335 for example covers issues of heterogeneity, 
looking at meta-regression and treatment effects in subgroups. Individual patient data has a 
particularly important role in meta-regression. Regression and other methods for bias 
adjustment, including publication bias and so-called “small-study bias” will also be covered. 
Similarly, the introduction of network meta-analysis (Section 5) raises questions about 
inconsistency between “direct” and “indirect” evidence, which will be addressed in TSD4.28 
Here we will restrict attention to further extensions involving multiple outcomes. 
There are a huge variety of multiple outcome structures, only a minority of which have been 
examined in the context of evidence synthesis. One particularly important area for multiple 
outcome synthesis is where a set of eligible trials have been identified, but some report one 
outcome, some another, and perhaps others report both. The function of multiple outcome 
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synthesis in this case is to use all the available data, taking into account the correlation 
between outcomes at the within-trial (between-patient) level, and the between-trial level. 
Methods for doing this have been described by Riley and others.90,91 Readers may also refer 
to earlier work also based on multivariate normal methods.92,93  
A quite different form of multiple outcome synthesis occurs when different trials report a 
single outcome, but at different follow-up times. Further, some may report at several follow-
up times. Lu et al42 describe a series of piece-wise-constant hazard models that extend the 
cloglog models of Section 3.2, in that treatment effects are allowed to vary between time 
intervals.  
Multiple outcomes are often structurally related. For example, time-to-progression cannot 
post-date overall survival in cancer studies, and time to end of ‘flu cannot post-date time to 
the end of symptoms in studies of influenza treatments. Where possible, these structural 
constraints should be built into the synthesis. Burch et al94 and Welton et al95,96 provide 
examples. A further form of structural relation can be seen in trials on treatments for 
myocardial infarction, where trial evidence on an early intermediary outcome, coronary 
patency, can be combined with trial evidence on mortality.13,97   
Multiple reporting formats present further challenges for synthesis. Many of these are 
covered in the earlier section on shared parameter models (Section 4). A more complex 
example94,95 involved a synthesis that combined trials reporting median time to an event, 
mean time to an event, and proportion experiencing the event before a certain time. Results 
may also be reported separately for different subgroups, or collapsed over subgroups. Here, 
too, methods exist that make it possible to combine all the available information.98-101 
Another example of multiple reporting formats would be trials reporting on binary, 
categorical or continuous scales.57 
A final special topic is synthesis for Markov models. It seems clear that, for purposes of 
synthesis, it may be preferable to express Markov models in terms of transition rates rather 
than transition probabilities.102 This facilitates combining information from studies run over 
different follow-up periods, as explained in Section 3.2. It also gives the flexibility to model 
different treatment effects on different transitions (e.g. competing risks, Section 3.3), which is 
difficult to achieve with logit models. A further option is to combine data from studies where 
certain transitions are unobserved.102 Finally, it is worth mentioning that it is often open to 
question whereabouts in a Markov model a treatment effect is operating. Readers are referred 
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to recent work103 showing how treatment effects can be parameterised, synthesised and 
estimated in Markov rate models. 
 
9. DISCUSSION 
Our objective in this document has been to present a single unified account of evidence 
synthesis of aggregate data from RCTs, specifically but not exclusively for use in 
probabilistic decision making. In order to cover the variety of outcomes that are reported, and 
the range of data transformations required to obtain approximate linearity, we have set this 
within the familiar framework of Generalised Linear Models. This leads to a modular 
approach: different likelihoods and link functions may be employed, but the “synthesis” 
operation, which occurs at the level of the linear predictor, takes the exact same form in every 
case. The linear predictor, furthermore, is a regression model of a very specific type, with K-1 
treatment effect parameters for any K treatment network, offering a single model for pair-
wise meta-analysis, indirect comparisons, network meta-analysis (mixed treatment 
comparisons), and synthesis of multi-arm trials in any combination. This has all been 
presented in a Bayesian MCMC context and supported by code for WinBUGS 1.4.3.26 The 
use of WinBUGS dovetails with the GLM approach, as it allows us to take full advantage of 
the modularity implied by GLMs. 
This document brings together a great deal of previous work on Bayesian meta-analysis and 
MTC methods, and on meta-analysis methods for particular outcomes, into a single 
accessible and unified treatment and with a modular approach to computation. One aspect 
that may be considered novel is the application to synthesis of multi-arm trials. Although it 
would be relatively simple to extend all the commonly used estimators for use in meta-
analysis of multiple trials on the same K comparators, this does not appear to have been done. 
In our framework, however, the transitivity and exchangeability assumptions required for 
MTC automatically deliver multiple-treatment meta-analysis, and vice versa. 
In the course of the document we have raised the question: what is the relation between the 
arm-based analyses assumed in our models and software, with the far more common trial-
based summaries where the difference between treatments is taken as the data. With count 
data, there has always been a strong case for adopting an arm-based approach because it 
avoids normal approximations for the likelihood, and difficulties with zero cells. We have, 
however, brought to light a further problem with the arm-based approach, which is that with 
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multi-arm trials a correction must be made to the likelihood to account for correlations in the 
data. This applies to continuous outcome data as well as count data, and to both fixed and 
random effect models. With the appropriate correction to the likelihood, the results from arm-
based and treatment difference-based analyses are identical. Since all frequentist software for 
synthesis currently adopts the trial-level treatment difference approach, we can give a quite 
specific recommendation that this software should be avoided for multi-treatment syntheses 
with multi-arm trials, unless the correlation between relative treatment effects from the same 
trail can be appropriately accounted for. For syntheses where all trials are two-arm, there is 
no reason why frequentist methods should not be used, as long as statistically sound 
estimators are used and appropriate steps are taken to propagate parameter uncertainty, 
including correlations, through the decision model.  
Bayesian analysis is by no means a panacea: one area that clearly deserves more work is how 
to specify a “vague” prior distribution for the variance parameter. There can be little doubt 
that the vague priors that are generally recommended produce posteriors that are biased 
upwards. The extent of the bias is likely to be greater when the true variance is low, and when 
there is little data: either few trials or small trials, but this is also a problem when using 
frequentist estimators. The question could perhaps be resolved through a comprehensive 
simulation exercise. Although we can be reassured that the bias tends to be conservative, 
ultimately it may be preferable to use informative priors, perhaps tailored to particular 
outcomes and disease areas, based on studies of many hundreds of meta-analyses. This is 
currently an active research area.  
45,52,104,105 
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APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE 
This appendix gives illustrative WinBUGS code for all the link functions and likelihoods, as 
well as example code for shared parameter models. All programming code is fully annotated. 
The program codes are printed here, but are also available as WinBUGS system files at 
www.nicedsu.org.uk. Users are advised to download the WinBUGS files from the website 
instead of copying and pasting from this document. We have provided the codes as complete 
programs. However, the majority of each RE program is identical to other RE programs, and 
similarly for the FE programs. We have therefore highlighted the linear predictor in blue, and 
the likelihood and deviance calculations in red to emphasise the modular nature of the code. 
Tables A1 gives an index of the programmes and their relation to the descriptions in the text. 
Note that for each example there are random and fixed effects versions of the code. All fixed 
effects code can be run using the same data structure described for the random effects.   
 
Table A1 Index of WinBUGS code with details of examples and sections where they are described. 
Program 
number 
Fixed or 
Random Effects Likelihood 
Link 
Function 
Example 
name 
Model 
specification 
1 (a) Random (2-arm) Binomial logit Blocker Section 2.1 
 
(b) 
(c) 
(d) 
Fixed (2-arm) 
Random 
Fixed     
2 (a) Random Poisson log Dietary fat Section 3.1 
 (b) Fixed     
3 (a) Random Binomial cloglog Diabetes Section 3.2 
 (b) Fixed     
4 (a) Random Multinomial log 
Schizophren
ia Section 3.3 
 (b) Fixed     
5 (a) Random Normal identity Parkinson’s Section 3.4 
 (b) Fixed     
6 (a) Random Multinomial probit Psoriasis Section 3.6 
 (b) Fixed     
7 (a) Random Normal identity Parkinson’s Section 3.5 
 (b) Fixed (difference data)    
8 (a) Random Normal identity Parkinson’s Section 4 
 (b) Fixed (shared parameter)    
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EXAMPLE 1. BLOCKER 
The first two programmes (Blocker 1(a) and 1(b)) are somewhat apart from the other 
programmes: these programmes are only capable of processing syntheses of two treatments 
and 2-arm trials. We include them for the benefit of readers who may wish to start with the 
simplest possible case and see how the more general code that allows incorporation of multi-
arm trials is related to the simpler code. The Blocker example is described in Section 2.1. 
Program 1(a):  Binomial likelihood, logit link, Random Effects, two treatments (Blocker 
example). Two-arm trials Only 
# Binomial likelihood, logit link, pairwise meta-analysis (2 treatments) 
# Random effects model 
model{     # *** PROGRAM STARTS 
for(i in 1:ns){    #   LOOP THROUGH STUDIES 
    delta[i,1] <- 0    # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
    for (k in 1:2) {    #  LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])   # binomial likelihood 
        logit(p[i,k]) <- mu[i] + delta[i,k]    # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k]   # expected value of the numerators  
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   #Deviance contribution 
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
      } 
    resdev[i] <- sum(dev[i,])   #  summed residual deviance contribution for this trial 
    delta[i,2] ~ dnorm(d[2],tau)   # trial-specific LOR distributions 
  }    
totresdev <- sum(resdev[])   #Total Residual Deviance 
d[1]<- 0     # treatment effect is zero for reference treatment 
d[2] ~ dnorm(0,.0001)    # vague prior for treatment effect 
sd ~ dunif(0,5)    # vague prior for between-trial SD 
tau <- pow(sd,-2)       # between-trial precision = (1/between-trial variance) 
}      # *** PROGRAM ENDS 
 
The data structure has two components: a list specifying the number of studies ns and the 
main body of data which is in a column format: r[,1] and n[,1] are the numerators and 
denominators for the first treatment; r[,2] and n[,2], the numerators and denominators for the 
second listed treatment. Text can be included after the hash symbol (#) for ease of reference 
to the original data source. 
# Data (Blocker example) 
list(ns=22)    
 
r[,1] n[,1] r[,2] n[,2] # Study ID 
3 39 3 38 # 1 
14 116 7 114 # 2 
11 93 5 69 # 3 
127 1520 102 1533 # 4 
27 365 28 355 # 5 
6 52 4 59 # 6 
152 939 98 945 # 7 
48 471 60 632 # 8 
37 282 25 278 # 9 
188 1921 138 1916 # 10 
52 583 64 873 # 11 
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47 266 45 263 # 12 
16 293 9 291 # 13 
45 883 57 858 # 14 
31 147 25 154 # 15 
38 213 33 207 # 16 
12 122 28 251 # 17 
6 154 8 151 # 18 
3 134 6 174 # 19 
40 218 32 209 # 20 
43 364 27 391 # 21 
39 674 22 680 # 22 
END 
 
# Initial values 
#chain 1 
list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3)) 
Program 1(b):  Binomial likelihood, logit link, Fixed Effects, two treatments (Blocker 
example), Two-arm trials only. 
# Binomial likelihood, logit link, pairwise meta-analysis (2 treatments) 
# Fixed effect model 
model{     # *** PROGRAM STARTS 
for(i in 1:ns){    #   LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
    for (k in 1:2) {    #  LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
        logit(p[i,k]) <- mu[i] + d[k]    # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k]           # expected value of the numerators  
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   #Deviance contribution 
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))  
  } 
    resdev[i] <- sum(dev[i,])   #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])   #Total Residual Deviance 
d[1]<- 0     # treatment effect is zero for reference treatment 
d[2] ~ dnorm(0,.0001)    # vague prior for treatment effect 
}     # *** PROGRAM ENDS  
 
# Initial values 
#chain 1 
list(d=c( NA, 0),  mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2), mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3)) 
 
All code presented below is completely general and will be suitable for fitting pairwise or 
network meta-analyses with any number of treatments and multi-arm trials. We also provide 
an indication of the relevant parameters to monitor for inference and model checking for the 
various programs. 
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The nodes to monitor for the fixed effects models are the same as those for the random 
effects models, except that there is no heterogeneity parameter. 
This example and results are described in Section 2.1 of the paper (Table 1 and Table 2). The 
WinBUGS code for random effects is given in program 1(c) and the fixed effects code is 
given in program 1(d). 
Program 1(c): Binomial likelihood, logit link, Random Effects (Blocker example) 
# Binomial likelihood, logit link 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     # LOOP THROUGH STUDIES 
     w[i,1] <- 0     # adjustment for multi-arm trials is zero for control arm 
     delta[i,1] <- 0     # treatment effect is zero for control arm 
     mu[i] ~ dnorm(0,.0001)    # vague priors for all trial baselines 
     for (k in 1:na[i])  {    #  LOOP THROUGH ARMS 
          r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
          logit(p[i,k]) <- mu[i] + delta[i,k]   # model for linear predictor 
          rhat[i,k] <- p[i,k] * n[i,k]    # expected value of the numerators  
          dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))  #Deviance contribution 
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))  
      } 
     resdev[i] <- sum(dev[i,1:na[i]])   #  summed residual deviance contribution for this trial 
     for (k in 2:na[i]) {     # LOOP THROUGH ARMS 
          delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions 
          md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]    # mean of LOR distributions (with multi-arm trial correction) 
          taud[i,k] <- tau *2*(k-1)/k   # precision of LOR distributions (with multi-arm trial correction) 
          w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])  # adjustment for multi-arm RCTs 
          sw[i,k] <- sum(w[i,1:k-1])/(k-1)   # cumulative adjustment for multi-arm trials 
         } 
  }    
totresdev <- sum(resdev[])    #Total Residual Deviance 
d[1] <- 0      # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
sd ~ dunif(0,5)     # vague prior for between-trial SD. ALTERNATIVES BELOW  
tau <- pow(sd,-2)     # between-trial precision = (1/between-trial variance) 
}      # *** PROGRAM ENDS  
 
Alternative prior distributions can be used for the Random Effects Variance. For example, the 
last two lines above can be replaced by a vague Gamma prior on the precision parameter, 
which is sometimes also referred to as a vague inverse Gamma prior on the variance: 
 
tau ~ dgamma(.001,.001)   # vague gamma prior on the precision  
sd <- pow(tau,-0.5)  
 
See Section 6.2 in the main document for further discussion of prior distributions. 
Additional code can be added before the closing brace to estimate all the pair-wise Log Odds 
Ratios and Odds Ratios, to generate ranking statistics and the probability that each treatment 
is the best treatment, and to produce estimates of absolute effects, given additional 
information on the absolute treatment effect on one of the treatments. In addition, given an 
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assumption about the absolute effect of one treatment, it is possible to express the treatment 
effect on other scales (risk difference, relative risk), or number needed to treat, and to obtain 
confidence intervals for all these quantities. This is illustrated below. 
 
################################################################################ 
# Extra code for all odds ratios and log odds ratios, ranking, and absolute effects, and relative effects 
# on alternative scales: Numbers Needed to Treat, Risk Difference, Relative Risks 
################################################################################ 
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2 
for (c in 1:(nt-1)) {   
     for (k in (c+1):nt)  {  
          or[c,k] <- exp(d[k] - d[c]) 
          lor[c,k] <- (d[k]-d[c]) 
         }   
     } 
 
# ranking on relative scale 
for (k in 1:nt) {  
      rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
#    rk[k] <- rank(d[],k) # assumes events are “bad” 
      best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
      for (h in 1:nt){  prob[h,k] <- equals(rk[k],h)  } # calculates probability that treat k is h-th best 
     } 
 
# Provide estimates of treatment effects T[k] on the natural (probability) scale  
# Given a Mean Effect, meanA, for ‘standard’ treatment 1, with precision (1/variance) precA 
A ~ dnorm(meanA,precA) 
for (k in 1:nt) { logit(T[k]) <- A + d[k]  } 
 
# Provide estimates of number needed to treat NNT[k], Risk Difference RD[k],  
# and Relative Risk RR[k], for each treatment, relative to treatment 1 
for (k in 2:nt) {  
    NNT[k] <- 1/(T[k] - T[1]) # assumes events are “good” 
#  NNT[k] <- 1/(T[1]- T[k]) # assumes events are “bad” 
    RD[k] <- T[k] - T[1] 
    RR[k] <- T[k]/T[1] 
   } 
 
The data structure has two components: a list specifying the number of treatments nt and 
number of studies ns. Both data components need to be loaded into WinBUGS for the 
program to run. The main body of data is in a vector format, in the order r[,1]  then n[,1], the 
numerators and denominators for the first treatment,  then r[,2]  then n[,2], the numerators and 
denominators for the second listed treatment, then t[,1] and t[,2], the treatment number 
identifiers for the first and second listed treatments, and finally the number of arms in each 
trial, na[]. The purpose for this structure becomes clearer in datasets with multi-arm trials. An 
important feature of the code presented is the assumption that the treatments are always 
presented in ascending (numerical) order and that treatment 1 is taken as the reference 
treatment. This rule is crucial when conducting network meta-analysis to ensure the correct 
relative effects are estimated.  
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We strongly recommend the use of the column data format shown here in preference to the 
list format that WinBUGS also allows, and the use of comments to add trial names or 
references. This facilitates data checking. 
 
# Data (Blocker example) 
list(nt=2, ns=22) 
 
r[,1] n[,1] r[,2] n[,2] t[,1] t[,2] na[] 
3 39 3 38 1 2 2 
14 116 7 114 1 2 2 
11 93 5 69 1 2 2 
127 1520 102 1533 1 2 2 
27 365 28 355 1 2 2 
6 52 4 59 1 2 2 
152 939 98 945 1 2 2 
48 471 60 632 1 2 2 
37 282 25 278 1 2 2 
188 1921 138 1916 1 2 2 
52 583 64 873 1 2 2 
47 266 45 263 1 2 2 
16 293 9 291 1 2 2 
45 883 57 858 1 2 2 
31 147 25 154 1 2 2 
38 213 33 207 1 2 2 
12 122 28 251 1 2 2 
6 154 8 151 1 2 2 
3 134 6 174 1 2 2 
40 218 32 209 1 2 2 
43 364 27 391 1 2 2 
39 674 22 680 1 2 2 
END 
 
# Initial values 
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3)) 
 
To obtain the posterior summaries of the parameters of interest for inference, the nodes d and 
sd (in the random effects model only) need to be monitored. To obtain the posterior means of 
the parameters required to assess model fit and model comparison, dev, totresdev and the DIC 
(from the WinBUGS DIC tool), need to be monitored.  In addition, to calculate the leverage 
for each data point and to draw leverage plots, rhat needs to be monitored. 
Program 1(d):  Binomial likelihood, logit link, Fixed Effects (Blocker example) 
# Binomial likelihood, logit link 
# Fixed effects model 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     # LOOP THROUGH STUDIES 
     mu[i] ~ dnorm(0,.0001)    # vague priors for all trial baselines 
     for (k in 1:na[i])  {    #  LOOP THROUGH ARMS 
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          r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
          logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]  # model for linear predictor 
          rhat[i,k] <- p[i,k] * n[i,k]    # expected value of the numerators  
          dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))      #Deviance contribution 
             +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))    
        } 
     resdev[i] <- sum(dev[i,1:na[i]])   # summed residual deviance contribution for this trial 
     }    
totresdev <- sum(resdev[])    #Total Residual Deviance 
d[1]<-0      # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
}      # *** PROGRAM ENDS  
 
# Initial values 
#chain 1 
list(d=c( NA, 0), mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2),  mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3)) 
 
 
EXAMPLE 2.  DIETARY FAT 
In a Cochrane Review of randomised controlled trials to assess the effect of change in dietary 
fats on total and cardiovascular mortality,104 data extracted was in the form of rates and given 
as the number of events per person-years observed (Table A2).   
 
Table A2 Dietary fat example: Study names and treatment codes for the 10 included studies and person-
years and total mortality observed in each study. 
 Treatment Person-yrs obs Total mortality Number randomised 
 control diet diet 2 control diet diet 2 control diet diet 2 control diet diet 2 
Study name and ID t[,1] t[,2] t[,3] E[,1] E[,2] E[,3] r[,1] r[,2] r[,3] n[,1] n[,2] n[,3] 
1.DART 1 2  1917 1925  113 111  1015 1018  
2.London Corn /Olive 1 2 2 43.6 41.3 38 1 5 3 26 28 26 
3.London Low Fat 1 2  393.5 373.9  24 20  129 123  
4.Minnesota Coronary 1 2  4715 4823  248 269  4516 4516  
5.MRC Soya 1 2  715 751  31 28  194 199  
6.Oslo Diet-Heart 1 2  885 895  65 48  206 206  
7.STARS 1 2  87.8 91  3 1  30 30  
8.Sydney Diet-Heart 1 2  1011 939  28 39  237 221  
9.Veterans Administration 1 2  1544 1588  177 174  422 424  
10.Veterans Diet & Skin CA 1 2  125 123  2 1  67 66  
 
Most of the trials compared only one reduced fat dietary intervention with a control diet (non-
reduced fat). However, the ‘London Corn/Olive’ trial compared two types of reduced fat diets 
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against control (for more details see Hooper et al.104). For the purpose of this example we 
considered the two different types of diet as the same intervention (treatment 2), but kept the 
treatment arms separately, so that in a random effects model, this trial will provide two 
correlated estimates of the trial-specific treatment effect δi,12 and in the fixed effects model, 
both arms will contribute to the estimate of the common treatment effect d12.  
The model for this type of data is outlined in Section 3.1. The WinBUGS code for random 
effects is given in program 2(a) and the fixed effects code is given in program 2(b).   
Program 2(a):  Poisson likelihood, log link, Random Effects (Dietary fat example) 
# Poisson likelihood, log link 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     # LOOP THROUGH STUDIES 
    w[i,1] <- 0     # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0     # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)    # vague priors for all trial baselines 
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        r[i,k] ~ dpois(theta[i,k])    # Poisson likelihood 
        theta[i,k] <- lambda[i,k]*E[i,k]   # failure rate * exposure 
        log(lambda[i,k]) <- mu[i] + delta[i,k]   # model for linear predictor 
        dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) #Deviance contribution 
     } 
    resdev[i] <- sum(dev[i,1:na[i]])   #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {     # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])   # trial-specific LOR distributions 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]      # mean of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k     # precision of LOR distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])  # adjustment for multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)    # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])    #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)     # between-trial precision = (1/between-trial variance) 
}       # *** PROGRAM ENDS  
 
As before, additional code can be added to monitor all the K(K-1)/2 log hazard ratios and 
hazard ratios when there are more than 2 treatments: 
 
# pairwise HRs and LHRs for all possible pair-wise comparisons, if nt>2 
for (c in 1:(nt-1)) {    
       for (k in (c+1):nt)  {   
              lhr[c,k] <- (d[k]-d[c]) 
              log(hr[c,k]) <- lhr[c,k] 
         }   
     } 
 
or to rank treatments and monitor the probabilities that each is best, and to generate absolute 
rates for each treatment. For example if, on the basis of some external data we believe that 
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the log-rate for Treatment 1 has mean -3, and precision 1.77, then we can generate absolute 
rates for other treatments as follows: 
 
A ~ dnorm(-3,1.77) 
for (k in 1:nt) { log(T[k]) <- A + d[k]  } 
 
A further variable that may be required for cost-effectiveness modelling might be the 
proportion of patients that would be expected to have an event, after a follow-up of, say, 3 
months, under each treatment. In this example the rates are per year, so: 
 
for (k in 1:nt) { p[k] <- 1-exp(-T[k]*0.25)  } 
 
The data structure again has two components: a list specifying the number of treatments nt 
and number of studies ns. Both data components need to be loaded into WinBUGS for the 
program to run. The main body of data is in a vector format, and we need to allow for a 3-arm 
trial. Three places are therefore required to specify the treatments t[,], the exposure times E[,] 
and the number of events r[,] in each arm; “NA” indicates that the data is missing for a 
particular cell. As before na[] is the number of arms in each study. Text can be included after a 
hash symbol for ease of reference to the original data source. 
 
# Data (Dietary fat example) 
list(ns=10, nt=2)    
 
t[,1] t[,2] t[,3] E[,1] E[,2] E[,3] r[,1] r[,2] r[,3] na[] #ID 
1 2 NA 1917 1925 NA 113 111 NA 2 #2 DART 
1 2 2 43.6 41.3 38 1 5 3 3 #10 London Corn /Olive 
1 2 NA 393.5 373.9 NA 24 20 NA 2 #11 London Low Fat 
1 2 NA 4715 4823 NA 248 269 NA 2 #14 Minnesota Coronary 
1 2 NA 715 751 NA 31 28 NA 2 #15 MRC Soya 
1 2 NA 885 895 NA 65 48 NA 2 #18 Oslo Diet-Heart 
1 2 NA 87.8 91 NA 3 1 NA 2 #22 STARS 
1 2 NA 1011 939 NA 28 39 NA 2 #23 Sydney Diet-Heart 
1 2 NA 1544 1588 NA 177 174 NA 2 #26 Veterans Administration 
1 2 NA 125 123 NA 2 1 NA 2        #27 Veterans Diet & Skin CA 
END 
 
# Initial Values  
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0)) 
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To get the posterior summaries of the parameters of interest for inference, the nodes d and sd 
(in the random effects model only) need to be monitored. To obtain the posterior means of 
the parameters required to assess model fit and model comparison, dev, totresdev and the DIC 
(from the WinBUGS the DIC tool), need to be monitored.  In addition, to calculate the 
leverage for each data point and to draw leverage plots, theta needs to be monitored. 
Program 2(b):  Poisson likelihood, log link, Fixed Effects (Dietary fat) 
# Poisson likelihood, log link 
# Fixed effects model for multi-arm trials 
model{       # *** PROGRAM STARTS 
for(i in 1:ns){      #   LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)     # vague priors for all trial baselines 
    for (k in 1:na[i]) {      #  LOOP THROUGH ARMS 
        r[i,k] ~ dpois(theta[i,k])     # Poisson likelihood 
        theta[i,k] <- lambda[i,k]*E[i,k]    # event rate * exposure 
        log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]   # model for linear predictor 
        dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k]))     #Deviance contribution 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])    #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])     #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }    # vague priors for treatment effects 
}       # *** PROGRAM ENDS  
 
# Initial Values 
#chain 1 
list(d=c( NA, 0), mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) 
#chain 2 
list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) 
#chain 3 
list(d=c( NA, 2), mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0)) 
RESULTS 
The results from the two models (3 chains: 20,000 iterations after a burn-in of 20,000 for the 
FE model and 100,000 iterations after a burn-in of 100,000 for the RE model) are compared 
in Table A3. The random and fixed effects models are indistinguishable in terms of model fit, 
and both appear to fit the data well in that resD  is close to 21, the number of data points.  The 
posterior median of the pooled log-rate of a reduced fat diet, compared to the control diet is -
0.01 in the FE model with 95% Credible Interval (-0.11, 0.10) suggesting no difference in the 
number of cardiovascular mortalities in each group. The posterior medians of the absolute 
rates of mortality (and their 95% Credible intervals), having assumed that the log-rate of 
mortality on the control diet has mean -3 and precision 1.77, on the control and reduced fat 
diets are the same (Table A3).   
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Table A3 Dietary fat example: posterior mean, standard deviation (sd), median and 95% Credible 
interval (CrI) for both the fixed and random effects models for the treatment effect d12, absolute effects of 
the control diet (T1) and the reduced fat diet (T2) for a log-rate of mortality on the control diet with mean -
3 and precision 1.77, heterogeneity parameter τ and model fit statistics. 
 FE model RE model 
 mean sd median CrI mean sd median CrI 
d12 -0.01 0.054 -0.01 (-0.11,0.10) -0.02 0.09 -0.01 (-0.19,0.16) 
T1 0.06 0.04 0.05 (0.01,0.18) 0.06 0.04 0.05 (0.01,0.18) 
T2 0.06 0.04 0.05 (0.01,0.18) 0.06 0.04 0.05 (0.01,0.18) 
τ - - - - 0.13 0.12 0.10 (0.00,0.43) 
resD * 22.32    21.5    
pD 10.9    13.3    
DIC 33.2    34.8    
* Compare to 21 data points  
 
EXAMPLE 3. DIABETES 
Here we show code for a linear model on the log rate scale based on binomial data gathered 
at different follow-up times. We use as an illustration a network meta-analysis to assess the 
incidence of diabetes in randomised controlled trials of antihypertensive drugs.105 The 
outcome was new cases of diabetes observed over the trial duration period (measured in 
years) for 6 different drugs: Diuretic (treatment 1), Placebo (treatment 2), β blocker 
(treatment 3), CCB (treatment 4), ACE inhibitor (treatment 5) and ARB (treatment 6). In this 
example of a network meta-analysis, the reference treatment chosen was diuretic, as 
recommended in this field – for more details see Elliott & Meyer.105 The data are presented in 
Table A4 and the network diagram in Figure A3.  
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Table A4 Diabetes example: study names, follow-up time in years, treatments compared, total number of 
new cases of diabetes and number of patients in each trial arm, where Diuretic = treatment 1, Placebo = 
treatment 2, β blocker = treatment 3, CCB = treatment 4, ACE inhibitor = treatment 5 and ARB = 
treatment 6.105 
 
Study Follow-up 
(in years) 
Treatment 
New cases of 
diabetes Total number of patients 
 arm 1 arm 2 arm 3 arm 1 arm 2 arm 3 arm 1 arm 2 arm 3 
Study ID time[] t[,1] t[,2] t[,3] r[,1] r[,2] r[,3] n[,1] n[,2] n[,3] 
1.MRC-E 5.8 1 2 3 43 34 37 1081 2213 1102 
2.EWPH 4.7 1 2  29 20  416 424  
3.SHEP 3 1 2  140 118  1631 1578  
4.HAPPHY 3.8 1 3  75 86  3272 3297  
5.ALLHAT 4 1 4 5 302 154 119 6766 3954 4096 
6.INSIGHT 3 1 4  176 136  2511 2508  
7.ANBP-2 4.1 1 5  200 138  2826 2800  
8.ALPINE 1 1 6  8 1  196 196  
9.FEVER 3.3 2 4  154 177  4870 4841  
10.DREAM 3 2 5  489 449  2646 2623  
11.HOPE 4.5 2 5  155 102  2883 2837  
12.PEACE 4.8 2 5  399 335  3472 3432  
13.CHARM 3.1 2 6  202 163  2721 2715  
14.SCOPE 3.7 2 6  115 93  2175 2167  
15.AASK 3.8 3 4 5 70 32 45 405 202 410 
16.STOP-2 4 3 4 5 97 95 93 1960 1965 1970 
17.ASCOT 5.5 3 4  799 567  7040 7072  
18.NORDIL 4.5 3 4  251 216  5059 5095  
19.INVEST 4 3 4  665 569  8078 8098  
20.CAPPP 6.1 3 5  380 337  5230 5183  
21.LIFE 4.8 3 6  320 242  3979 4020  
22.VALUE 4.2 4 6  845 690  5074 5087  
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Figure A3 Diabetes network: each edge represents a treatment, connecting lines indicate pairs of 
treatments which have been directly compared in randomised trials. The numbers on the lines indicate 
the numbers of trials making that comparison and the numbers by the treatment names are the treatment 
codes used in the modelling. 
 
The model for this type of data is outlined in Section 3.2. The WinBUGS code for random 
effects is given in program 3(a) and the fixed effects code is given in program 3(b).   
Program 3(a):  Binomial likelihood, cloglog link, Random Effects (Diabetes example) 
# Binomial likelihood, cloglog link 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     #   LOOP THROUGH STUDIES 
    w[i,1] <- 0     # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0     # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)    # vague priors for all trial baselines 
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # Binomial likelihood 
        cloglog(p[i,k]) <- log(time[i]) + mu[i] + delta[i,k]     # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k]    # expected value of the numerators  
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))    
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) #Deviance contribution 
} 
    resdev[i] <- sum(dev[i,1:na[i]])   #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {     # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])    # trial-specific LOR distributions 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]   # mean of LOR distributions (with multi-arm correction) 
        taud[i,k] <- tau *2*(k-1)/k    # precision of LOR distributions (with multi-arm correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])  # adjustment for multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)    # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])    #Total Residual Deviance 
d[1]<-0      # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
ACE inhibitor
(5)
Diuretic
(1)
β blocker
(3)
CCB (4)
Placebo
(2)
ARB
(6)
3
2
2
2
1
1
1
3
2
5
3
1
3
1
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sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)     # between-trial precision = (1/between-trial variance) 
}       # *** PROGRAM ENDS  
 
Additional code to generate all the treatment contrasts, absolute effects, ranking can be 
added, as with the Poisson – log link models.  To generate absolute probabilities for each 
treatment, if, on the basis of some external data, we believe that the cloglog of the probability 
of an event for Treatment 1, after a time period of 3 years, has mean -4.2, and precision 1.11, 
then we can generate absolute probabilities for other treatments as follows: 
 
A ~ dnorm(-4.2,1.11) 
for (k in 1:nt) { cloglog(T[k]) <- log(3) + A + d[k]  } 
 
The main body of data is in the same format as the binomial likelihood with logit link in 
Example 1, with an additional vector for follow-up time, time[]. Note that treatments are 
ordered numerically so that the treatment in arm 2 has a higher code than the treatment in arm 
1, and the treatment in arm 3 has a higher code than the treatment in arm 2. This is essential 
to ensure the correct relative effects are obtained. 
 
# Data (Diabetes example) 
list(ns=22, nt=6)    
 
time[] t[,1] r[,1] n[,1] t[,2] r[,2] n[,2] t[,3] r[,3] n[,3] na[] #Study 
5.8 1 43 1081 2 34 2213 3 37 1102 3 #MRC-E 38 
4.7 1 29 416 2 20 424 NA NA NA 2 #EWPH 32 
3 1 140 1631 2 118 1578 NA NA NA 2 #SHEP 42 
3.8 1 75 3272 3 86 3297 NA NA NA 2 #HAPPHY33 
4 1 302 6766 4 154 3954 5 119 4096 3 #ALLHAT 26 
3 1 176 2511 4 136 2508 NA NA NA 2 #INSIGHT35 
4.1 1 200 2826 5 138 2800 NA NA NA 2 #ANBP-2 18 
1 1 8 196 6 1 196 NA NA NA 2 #ALPINE 27 
3.3 2 154 4870 4 177 4841 NA NA NA 2 #FEVER 20 
3 2 489 2646 5 449 2623 NA NA NA 2 #DREAM 31 
4.5 2 155 2883 5 102 2837 NA NA NA 2 #HOPE 34 
4.8 2 399 3472 5 335 3432 NA NA NA 2 #PEACE 40 
3.1 2 202 2721 6 163 2715 NA NA NA 2 #CHARM 30 
3.7 2 115 2175 6 93 2167 NA NA NA 2 #SCOPE 41 
3.8 3 70 405 4 32 202 5 45 410 3 #AASK 25 
4 3 97 1960 4 95 1965 5 93 1970 3 #STOP-2 43 
5.5 3 799 7040 4 567 7072 NA NA NA 2 #ASCOT 28 
4.5 3 251 5059 4 216 5095 NA NA NA 2 #NORDIL 39 
4 3 665 8078 4 569 8098 NA NA NA 2 #INVEST 36 
6.1 3 380 5230 5 337 5183 NA NA NA 2 #CAPPP 29 
4.8 3 320 3979 6 242 4020 NA NA NA 2 #LIFE 37 
4.2 4 845 5074 6 690 5087 NA NA NA 2 #VALUE 44 
END 
 
# Initial Values  
# In this case it is advisable to initialise delta to avoid numerical errors 
#chain 1 
list(d=c(NA,0,0,0,0,0),  sd=1,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0), 
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delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 
0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, 
NA, 0, NA), .Dim=c(22, 3))) 
#chain 2 
list(d=c(NA,-1,4,-1,2,3),  sd=3,  mu=c(1,1,0,1,0,    0,1,0,0,0,    1,1,0,0,0,   0,1,0,0,0,  1,1), 
delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 
0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, 
NA, 0, NA), .Dim=c(22, 3))) 
#chain 3 
list(d=c(NA,1,4,-3,-2,3),  sd=4.5,  mu=c(1,1,0,1,0,    0,1,0,0,0,    1,1,0,-2,0,   0,1,0,-2,0,  1,1), 
delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 
0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, 
NA, 0, NA), .Dim=c(22, 3))) 
Program 3(b):  Binomial likelihood, cloglog link, Fixed Effects (Diabetes example) 
# Binomial likelihood, cloglog link 
# Fixed effects model  
model{       # *** PROGRAM STARTS 
for(i in 1:ns){      # LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)     # vague priors for all trial baselines 
    for (k in 1:na[i]) {      # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])     # Binomial likelihood 
        cloglog(p[i,k]) <- log(time[i]) + mu[i] + d[t[i,k]] - d[t[i,1]]     # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k]     # expected value of the numerators  
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))     #Deviance contribution 
} 
    resdev[i] <- sum(dev[i,1:na[i]])     #  summed residual deviance contribution for this trial 
}    
totresdev <- sum(resdev[])     #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }    # vague priors for treatment effects 
}       # *** PROGRAM ENDS  
 
# Initial Values  
#chain 1 
list(d=c(NA,0,0,0,0,0),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0) ) 
#chain 2 
list(d=c(NA,1,1,1,1,1),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0)  ) 
#chain 3 
list(d=c(NA,1,1,1,1,2),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0)  ) 
RESULTS 
Both fixed and random effects models were fitted (3 chains: 100,000 iterations after a burn-in 
of 50,000). From the results presented in Table A5, we see that the fixed effects model has a 
very poor fit and the random effects model should be preferred for inference.   
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Table A5 Diabetes example: posterior mean, standard deviation (sd), median and 95% Credible interval 
(CrI) for both the fixed and random effects models for the treatment effects of Placebo (d12), β blocker 
(d13), CCB (d14), ACE inhibitor (d15) and ARB (d16) relative to Diuretic; absolute effects of diuretic (T1) 
Placebo (T2), β blocker (T3), CCB (T4), ACE inhibitor (T5) and ARB (T6); heterogeneity parameter τ and 
model fit statistics. 
 FE model RE model 
 mean sd median CrI mean sd median CrI 
d12 -0.25 0.06 -0.25 (-0.36,-0.14) -0.29 0.09 -0.29 (-0.47,-0.12) 
d13 -0.06 0.06 -0.06 (-0.17,0.05) -0.07 0.09 -0.07 (-0.25,0.10) 
d14 -0.25 0.05 -0.25 (-0.36,-0.15) -0.24 0.08 -0.24 (-0.41,-0.08) 
d15 -0.36 0.05 -0.36 (-0.46,-0.25) -0.40 0.09 -0.40 (-0.58,-0.24) 
d16 -0.45 0.06 -0.45 (-0.58,-0.33) -0.47 0.11 -0.47 (-0.70,-0.27) 
T1 0.065 0.067 0.044 (0.01,0.25) 0.065 0.067 0.044 (0.01,0.25) 
T2 0.052 0.055 0.034 (0.01,0.20) 0.050 0.053 0.033 (0.01,0.20) 
T3 0.062 0.064 0.042 (0.01,0.24) 0.061 0.064 0.041 (0.01,0.24) 
T4 0.051 0.055 0.034 (0.01,0.20) 0.052 0.056 0.035 (0.01,0.20) 
T5 0.047 0.050 0.031 (0.00,0.18) 0.045 0.048 0.030 (0.00,0.18) 
T6 0.043 0.046 0.028 (0.00,0.17) 0.042 0.046 0.028 (0.00,0.17) 
τ     0.13 0.04 0.12 (0.05,0.23) 
resD * 78.25    53.7    
pD 27.0    38.0    
DIC 105.2    91.7    
* Compare to 48 data points  
 
The posterior median of the pooled treatment effects, on the complementary log-log scale, of 
treatments 2 to 6 relative to the reference treatment show a beneficial effect of all the 
treatment with the exception of treatment 3 (Table A5).  
The posterior medians of the absolute probabilities of developing diabetes after a period of 
three years, assuming that the cloglog of the probability of developing diabetes on Placebo 
has mean -4.2 and precision 1.11, on each of the treatments are between 3 and 4% (Table 
A5). 
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EXAMPLE 4. SCHIZOPHRENIA 
In a network meta-analysis of trials of antipsychotic medication for the prevention of relapse 
in people with schizophrenia, 17 trials comparing 9 treatments including placebo were 
included.45 The data available from each trial are the number of patients in each of three 
outcome states at the end of follow-up.  The outcome states are: relapse (j=1), discontinuation 
of treatment due to intolerable side effects (j=2), and discontinuation for other reasons (j=3), 
which might include inefficacy of treatment that did not fulfil all criteria for relapse, or loss 
to follow-up. Patients not reaching any of these end-points at the end of follow-up were 
considered as censored observations, and still in remission (j=4) (for more details see Ades et 
al.45). The data are presented in Table A6 and the network diagram in Figure A4. 
 
Table A6 Schizophrenia example: study names, follow-up time in weeks, treatments compared, total 
number of events for each of the four states and total number of patients in each trial arm, where Placebo 
= treatment 1, Olanzapine = 2, Amisulpride = 3, Zotepine = 4, Aripripazole = 5, Ziprasidone = 6, 
Paliperidone = 7, Haloperidol = 8, Risperidone = 9.45 
    number of events   
 follow-
up  
(weeks) 
treatment relapse 
discontinuation 
due to 
intolerable side 
effects 
discontinuation for 
other reasons 
Patient still in 
remission 
total no of 
patients 
  arm 1 arm 2 arm 1 arm 2 arm 1 arm 2 arm 1 arm 2 arm 1 arm 2 arm 1 arm 2 
Study f[] t[,1] t[,2] r[,1,1] r[,2,1] r[,1,2] r[,2,2] r[,1,3] r[,2,3] r[,1,4] r[,2,4] n[,1] n[,2] 
1 42 1 2 28 9 12 2 15 19 47 194 102 224 
2 46 1 2 7 10 0 2 4 16 2 17 13 45 
3 46 1 2 5 6 2 10 5 15 2 17 14 48 
4 26 1 3 5 4 5 1 39 26 23 38 72 69 
5 26 1 4 21 4 4 16 24 21 9 20 58 61 
6 26 1 5 85 50 13 16 12 18 45 71 155 155 
7 52 1 6 43 71 11 19 7 28 10 88 71 206 
8 47 1 7 52 23 1 3 7 17 41 61 101 104 
9 28 2 6 11 8 6 5 44 33 10 9 71 55 
10 52 2 8 87 34 54 20 170 50 316 76 627 180 
11 52 2 8 28 29 9 14 26 25 78 66 141 134 
12 28 2 9 20 53 17 17 36 18 99 79 172 167 
13 52 3 8 5 9 3 5 2 2 19 15 29 31 
14 52 8 9 65 41 29 22 80 60 14 54 188 177 
15 104 8 9 8 4 0 3 4 4 18 22 30 33 
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Figure A4 Schizophrenia network: each edge represents a treatment, connecting lines indicate pairs of 
treatments which have been directly compared in randomised trials. The numbers on the lines indicate 
the numbers of trials making that comparison and the numbers by the treatment names are the treatment 
codes used in the modelling. 
 
A random effects model with different between-trial variation for each outcome and a fixed 
effects model were fitted, as outlined in Section 3.3. The WinBUGS code for the random 
effects model is given in program 4(a), and the fixed effect code is given in program 4(b).   
Program 4(a):  Multinomial likelihood (with competing risks), log link, Random Effects 
(Schizophrenia example) 
# Multinomial likelihood, log link (competing risks) 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     #   LOOP THROUGH STUDIES 
    for (m in 1:3) {     # LOOP OVER 3 ENDPOINTS 
        w[i,1,m] <- 0      # adjustment for multi-arm trials is zero for control arm 
        delta[i,1,m] <- 0    # treatment effect is zero for control arm 
        mu[i,m] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
      }  
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        r[i,k,1:4] ~ dmulti(p[i,k,1:4],n[i,k])   # multinomial likelihood 
        p[i,k,4] <- 1 - sum(p[i,k,1:3]) 
        slam[i,k] <- sum(lamda[i,k,])    # sum of the 3 hazard rates 
        for (m in 1:4) {      # LOOP OVER ALL ENDPOINTS 
            rhat[i,k,m] <- p[i,k,m]*n[i,k]       # predicted number events  
            dv[i,k,m] <- 2*r[i,k,m]*log(r[i,k,m]/rhat[i,k,m])      #Deviance contribution 
          } 
        dev[i,k] <- sum(dv[i,k,])    # deviance contribution for arm 
        for (m in 1:3) {     # LOOP THROUGH 3 ENDPOINTS  
# cumulative pr(failed) at each end point (per year), data in weeks 
            p[i,k,m] <- lamda[i,k,m] * (1-exp(-slam[i,k]*f[i]/52))/slam[i,k]     
Aripiprazole
(5)
Placebo
(1)
Amisulpride
(3)
Zotepine
(4)
Olanzapine
(2)
Ziprasidone
(6)
Paliperidone
(7)
Risperidone
(9)
Haloperidol
(8)3
1
1
1
1
1
1
2
1
1
2
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            log(lamda[i,k,m]) <- mu[i,m] + delta[i,k,m]     # model for linear predictor for each outcome 
        for (k in 2:na[i]) {    # LOOP THROUGH ARMS 
            delta[i,k,m] ~ dnorm(md[i,k,m],taud[i,k,m]) 
            md[i,k,m] <- d[t[i,k],m] - d[t[i,1],m] + sw[i,k,m]    # mean of LHR distributions (with multi-arm correction) 
            taud[i,k,m] <- tau[m] *2*(k-1)/k       # precision of LHR distributions with multi-arm correction 
            w[i,k,m] <- (delta[i,k,m] - d[t[i,k],m] + d[t[i,1],m])     # adjustment for multi-arm RCTs 
            sw[i,k,m] <- sum(w[i,1:k-1,m])/(k-1)   # cumulative adjustment for multi-arm trials 
          } 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])   #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])     #Total Residual Deviance 
for (m in 1:3) {     # LOOP THROUGH 3 END-POINTS 
    d[1,m]<-0     # treatment effect is zero for reference treatment 
    for (k in 2:nt){  d[k,m] ~ dnorm(0,.0001) }  # vague priors for treatment effects 
    sd[m] ~ dunif(0,5)    # vague prior for between-trial SD 
    tau[m] <- pow(sd[m],-2)    # between-trial precision = (1/between-trial variance) 
  } 
}       # *** PROGRAM ENDS  
 
Additional code to monitor all treatment contrasts and rank treatments can be added as 
before. Given values for the mean for each outcome, meanA = c(-0.078,-1.723,-0.7185), and precision, 
precA = c(1.6, 1.05, 0.61), of the hazards for each endpoint on Treatment 1, from external sources, 
absolute effects, and absolute probabilities of the competing outcomes occurring within a 
given time period, timeA, say, a 1-month (1/12=0.083 years) interval, could be monitored as 
follows: 
 
for (k in 1:nt) {pslam(k] <- sum(T[k,]) }       #LOOP THROUGH TREATMENTS, summing the 3 rates 
for (m in 1:3) {     # LOOP THROUGH 3 END-POINTS 
    A[m] ~ dnorm(meanA[m],precA[m]) 
    for (k in 1:nt) {     # LOOP THROUGH TREATMENTS 
          log(T[k,m]) <- A[m] + d[k,m]   
          cumpr[k,m] <- T[k,m] * (1-exp(-pslam[k]*timeA))/pslam[k] # cumulative pr(failed) at each end point 
     } 
  } 
 
The data structure again consists of a list specifying the number of treatments nt and number 
of studies ns, with the main body of data in a vector format; f[] represents the follow-up time in 
that trial. Only two columns are required for each arm variable since there are no multi-arm 
trials: t[,1] then t[,2] the treatment codes; then r[,k,j] the number of events for the k-th treatment, 
outcome j; then n[,1] and n[,2] the total number of individuals in each trial arm; and finally the 
number of arms in the study, na[], and the study identifiers commented out. Both data 
components need to be loaded into WinBUGS for the program to run. 
 
# Data (Schizophrenia example) 
list(ns=15, nt=9)    
 
f[] t[,1] t[,2] r[,1,1] r[,2,1] r[,1,2] r[,2,2] r[,1,3] r[,2,3] r[,1,4] r[,2,4] n[,1] n[,2]
 na[] #study ID 
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42 1 2 28 9 12 2 15 19 47 194 102 224
 2 #1 
46 1 2 7 10 0 2 4 16 2 17 13 45
 2 #2 
46 1 2 5 6 2 10 5 15 2 17 14 48
 2 #3 
26 1 3 5 4 5 1 39 26 23 38 72 69
 2 #4 
26 1 4 21 4 4 16 24 21 9 20 58 61
 2 #5 
26 1 5 85 50 13 16 12 18 45 71 155 155
 2 #6 
52 1 6 43 71 11 19 7 28 10 88 71 206
 2 #7 
47 1 7 52 23 1 3 7 17 41 61 101 104
 2 #8 
28 2 6 11 8 6 5 44 33 10 9 71 55
 2 #9 
52 2 8 87 34 54 20 170 50 316 76 627 180
 2 #10 
52 2 8 28 29 9 14 26 25 78 66 141 134
 2 #11 
28 2 9 20 53 17 17 36 18 99 79 172 167
 2 #12 
52 3 8 5 9 3 5 2 2 19 15 29 31
 2 #13 
52 8 9 65 41 29 22 80 60 14 54 188 177
 2 #14 
104 8 9 8 4 0 3 4 4 18 22 30 33
 2 #15 
END 
 
# Initial Values  
# In this case it is advisable to initialise delta to avoid numerical errors 
#chain 1 
list(d= structure(.Data= c(NA, NA, NA,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0), .Dim=c(9, 3)),  
sd=c(1, 1, 1),  
mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  
0,0,0), .Dim=c(15, 3)),  
delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))   ) 
 
#chain 2 
list(d= structure(.Data= c(NA, NA, NA,   1,0,1,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,0,  0,1,0,  0,0,1), .Dim=c(9, 3)),  
sd=c(1, 2, 1.5),  
mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  
0,0,0), .Dim=c(15, 3)),  
delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))   ) 
 
#chain 3 
list(d= structure(.Data= c(NA, NA, NA,   -1,0,-1,  0,0,-1,  0,0,0,  0,0,-1,  0,0,0,  0,0,0,  0,-1,0,  0,0,-1), .Dim=c(9, 3)),  
sd=c(1, 2, 1.5),  
mu= structure(.Data= c(0,1,0,  0,1,0,  0,0,0,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,1,0,   0,1,0,  0,0,0,  0,0,0,  1,0,1,  
0,0,0), .Dim=c(15, 3)),  
delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  
NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))  ) 
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Readers experimenting with this example need to be aware of difficulties with starting values. 
We have found one set of starting values which converges, but to a different posterior. 
Examples like this remind us of the importance of careful attention to the technical aspects of 
fitting models by Bayesian MCMC, and the need to look at the results obtained with different 
starting values.  This is also an example where inverse gamma priors on the between trial 
variance leads to faster convergence, and avoids spikes in the posterior distributions.45 
Program 4(b):  Multinomial likelihood (with competing risks), log link, Fixed Effects 
(Schizophrenia example) 
# Multinomial likelihood, log link (competing risks) 
# Fixed effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){     #   LOOP THROUGH STUDIES 
    for (m in 1:3) {     # LOOP OVER 3 ENDPOINTS 
        w[i,1,m] <- 0     # adjustment for multi-arm trials is zero for control arm 
        delta[i,1,m] <- 0    # treatment effect is zero for control arm 
        mu[i,m] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
      } 
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        r[i,k,1:4] ~ dmulti(p[i,k,1:4],n[i,k])    # multinomial likelihood 
        p[i,k,4] <- 1 - sum(p[i,k,1:3]) 
        slam[i,k] <- sum(lamda[i,k,])    # sum of the 3 hazard rates 
        for (m in 1:4) {     # LOOP OVER ALL ENDPOINTS 
            rhat[i,k,m] <- p[i,k,m]*n[i,k]       # predicted number events (adjusting zero fitted values) 
            dv[i,k,m] <- 2*r[i,k,m]*log(r[i,k,m]/rhat[i,k,m])     #Deviance contribution 
          } 
        dev[i,k] <- sum(dev[i,k,])    # deviance contribution for arms 
        for (m in 1:3) {     # LOOP THORUGH ENDPOINTS 
            p[i,k,m] <- lamda[i,k,m] * (1-exp(-slam[i,k]*f[i]/52))/slam[i,k]   # cumulative pr(failed) at each end point 
            log(lamda[i,k,m]) <- mu[i,m] +  d[t[i,k],m] - d[t[i,1],m]   # model for linear predictor 
          } 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])   #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])    #Total Residual Deviance 
for (m in 1:3) {     # LOOP THORUGH ENDPOINTS 
    d[1,m]<-0      # treatment effect is zero for reference treatment 
    for (k in 2:nt){  d[k,m] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
  } 
}      # *** PROGRAM ENDS  
 
# Initial Values  
#chain 1 
list(d= structure(.Data= c(NA, NA, NA,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0), .Dim=c(9, 3)),  
mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  
0,0,0), .Dim=c(15, 3))   ) 
 
#chain 2 
list(d= structure(.Data= c(NA, NA, NA,   1,0,1,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,0,  0,1,0,  0,0,1), .Dim=c(9, 3)),  
mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  
0,0,0), .Dim=c(15, 3))   ) 
 
#chain 3 
list(d= structure(.Data= c(NA, NA, NA,   -1,0,-1,  0,0,-1,  0,0,0,  0,0,-1,  0,0,0,  0,0,0,  0,-1,0,  0,0,-1), .Dim=c(9, 3)),  
mu= structure(.Data= c(0,5,0,  0,5,0,  0,0,0,  0,0,5,  0,0,0,  0,0,5,  0,0,0,  0,0,5,  0,0,0,  0,5,0,   0,5,0,  0,0,0,  0,0,0,  3,0,3,  
0,0,0), .Dim=c(15, 3)))  
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RESULTS 
Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000 for the FE model and 
100,000 iterations after a burn-in of 10,000 for the RE model) are presented in Table A7. 
Note that the follow-up time data are entered in weeks, while the analysis delivers annual 
rates.  The model fit statistics suggest that the random effects model is a better fit to the data 
and the DIC shows that this model should be preferred. The log-hazard rates for each of the 
competing events and the absolute probabilities of the competing outcomes occurring within 
1 month (assuming a baseline log-hazard as detailed above) are given in Table A7.  For a 
graphical representation of which treatment is best for each of the competing outcomes and 
further comments see Ades et al.45 
 
Table A7 Schizophrenia example: posterior mean, standard deviation (sd), median and 95% Credible 
interval (CrI) for both the fixed and random effects models for the treatment effects of Olanzapine (d12), 
Amisulpride (d13), Zotepine (d14), Aripripazole (d15), Ziprasidone (d16), Paliperidone (d17), Haloperidol (d18) 
and Risperidone (d19) relative to Placebo, absolute probabilities of reaching each of the outcomes for 
Placebo (Pr1), Olanzapine (Pr2), Amisulpride (Pr3), Zotepine (Pr4), Aripripazole (Pr5), Ziprasidone (Pr6), 
Paliperidone (Pr7), Haloperidol (Pr8) and Risperidone (Pr9); heterogeneity parameter τ for each of the 
three outcomes, and model fit statistics for the fixed and random effects models. 
 FE model RE model 
 mean sd median CrI mean sd median CrI 
Relapse 
d12 -1.57 0.23 -1.57 (-2.01,-1.13) -1.46 0.48 -1.47 (-2.39,-0.50) 
d13 -1.15 0.48 -1.14 (-2.10,-0.22) -0.97 0.80 -0.97 (-2.53,0.63) 
d14 -2.10 0.23 -0.52 (-0.96,-0.06) -2.10 0.99 -2.08 (-4.11,-0.19) 
d15 -0.73 0.19 -0.72 (-1.10,-0.36) -0.73 0.82 -0.73 (-2.37,0.92) 
d16 -1.12 0.20 -1.12 (-1.50,-0.73) -1.23 0.65 -1.23 (-2.56,0.05) 
d17 -1.02 0.26 -1.01 (-1.53,-0.53) -1.02 0.84 -1.02 (-2.70,0.66) 
d18 -0.90 0.26 -0.90 (-1.41,-0.38) -0.69 0.64 -0.71 (-1.93,0.63) 
d19 -1.27 0.28 -1.27 (-1.82,-0.71) -1.12 0.74 -1.13 (-2.59,0.37) 
Pr1 0.09 0.07 0.07 (0.02,0.29) 0.09 0.07 0.07 (0.02,0.29) 
Pr2 0.02 0.02 0.02 (0.00,0.08) 0.03 0.03 0.02 (0.00,0.10) 
Pr3 0.03 0.04 0.02 (0.00,0.14) 0.05 0.07 0.03 (0.00,0.23) 
Pr4 0.01 0.02 0.01 (0.00,0.06) 0.02 0.04 0.01 (0.00,0.10) 
Pr5 0.05 0.04 0.03 (0.01,0.16) 0.06 0.08 0.03 (0.00,0.27) 
Pr6 0.03 0.03 0.02 (0.00,0.11) 0.03 0.05 0.02 (0.00,0.15) 
Pr7 0.03 0.03 0.02 (0.00,0.12) 0.04 0.06 0.02 (0.00,0.20) 
Pr8 0.04 0.04 0.03 (0.01,0.14) 0.06 0.07 0.04 (0.00,0.24) 
Pr9 0.03 0.03 0.02 (0.00,0.10) 0.04 0.06 0.02 (0.00,0.19) 
τ     0.73 0.32 0.66 (0.30,1.53) 
  
78 
 
Discontinuation due to side effects 
d12 -1.33 0.34 -1.33 (-2.01,-0.67) -1.07 0.89 -1.14 (-2.67,0.97) 
d13 -1.67 0.68 -1.64 (-3.09,-0.41) -1.75 1.39 -1.72 (-4.63,0.99) 
d14 1.15 0.59 1.12 (0.06,2.41) 1.14 1.56 1.12 (-2.05,4.34) 
d15 0.02 0.38 0.02 (-0.72,0.78) 0.02 1.49 0.02 (-3.10,3.12) 
d16 -1.05 0.34 -1.06 (-1.71,-0.35) -0.98 1.16 -1.02 (-3.28,1.52) 
d17 1.31 1.43 1.16 (-1.10,4.58) 1.35 2.05 1.24 (-2.48,5.76) 
d18 -0.90 0.39 -0.90 (-1.67,-0.15) -0.84 1.14 -0.86 (-3.16,1.56) 
d19 -1.34 0.42 -1.33 (-2.17,-0.52) -0.71 1.40 -0.89 (-3.08,2.63) 
Pr1 0.02 0.02 0.01 (0.00,0.09) 0.02 0.03 0.01 (0.00,0.09) 
Pr2 0.01 0.01 0.00 (0.00,0.03) 0.01 0.04 0.00 (0.00,0.07) 
Pr3 0.01 0.01 0.00 (0.00,0.03) 0.01 0.05 0.00 (0.00,0.06) 
Pr4 0.08 0.10 0.04 (0.00,0.35) 0.12 0.19 0.04 (0.00,0.82) 
Pr5 0.02 0.03 0.01 (0.00,0.10) 0.05 0.12 0.01 (0.00,0.38) 
Pr6 0.01 0.01 0.00 (0.00,0.04) 0.02 0.06 0.01 (0.00,0.11) 
Pr7 0.13 0.20 0.04 (0.00,0.84) 0.16 0.26 0.05 (0.00,0.97) 
Pr8 0.01 0.01 0.01 (0.00,0.04) 0.02 0.06 0.01 (0.00,0.11) 
Pr9 0.01 0.01 0.00 (0.00,0.03) 0.03 0.10 0.01 (0.00,0.26) 
τ     1.20 0.80 1.03 (0.14,3.31) 
Discontinuation due to other reasons 
d12 -0.52 0.23 -0.52 (-0.96,-0.06) -0.51 0.26 -0.52 (-0.99,0.03) 
d13 -0.60 0.25 -0.60 (-1.11,-0.11) -0.59 0.33 -0.60 (-1.23,0.07) 
d14 -0.48 0.32 -0.48 (-1.10,0.15) -0.48 0.40 -0.49 (-1.25,0.30) 
d15 0.24 0.38 0.23 (-0.50,1.00) 0.23 0.46 0.24 (-0.64,1.11) 
d16 -0.44 0.27 -0.44 (-0.96,0.10) -0.44 0.33 -0.45 (-1.06,0.24) 
d17 0.74 0.47 0.73 (-0.13,1.70) 0.75 0.52 0.76 (-0.26,1.79) 
d18 -0.43 0.26 -0.44 (-0.94,0.08) -0.43 0.32 -0.43 (-1.04,0.22) 
d19 -1.07 0.29 -1.07 (-1.64,-0.51) -1.08 0.36 -1.10 (-1.76,-0.33) 
Pr1 0.07 0.10 0.04 (0.00,0.37) 0.07 0.10 0.04 (0.00,0.37) 
Pr2 0.05 0.08 0.02 (0.00,0.26) 0.05 0.08 0.02 (0.00,0.27) 
Pr3 0.05 0.07 0.02 (0.00,0.24) 0.05 0.07 0.02 (0.00,0.25) 
Pr4 0.05 0.08 0.02 (0.00,0.27) 0.05 0.08 0.02 (0.00,0.27) 
Pr5 0.10 0.13 0.05 (0.00,0.49) 0.09 0.13 0.05 (0.00,0.49) 
Pr6 0.05 0.08 0.03 (0.00,0.28) 0.05 0.08 0.02 (0.00,0.29) 
Pr7 0.14 0.17 0.07 (0.00,0.66) 0.13 0.17 0.07 (0.00,0.66) 
Pr8 0.05 0.08 0.03 (0.00,0.28) 0.05 0.08 0.02 (0.00,0.29) 
Pr9 0.03 0.05 0.01 (0.00,0.16) 0.03 0.05 0.01 (0.00,0.16) 
τ     0.17 0.16 0.13 (0.00,0.59) 
resD * 120.0    89.1    
pD 68.5    80.2    
DIC 188.5    169.3    
*compare to 90 data points  
 
EXAMPLE 5. PARKINSON’S 
The data presented in Table A8 are the mean off-time reduction in patients given dopamine 
Agonists as adjunct therapy in Parkinson’s disease.  The data available are the mean, standard 
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deviation and number of patients in each trial arm, for 7 studies of five different drugs: 
placebo, coded 1, and five active drugs coded 2 to 5.  The network diagram is presented in 
Figure A5. The authors are grateful to Jeroen Jansen of Mapi Values for giving us access to 
this data. 
 
Table A8  Parkinson’s example: study names, treatments compared, mean off-time reduction with its 
standard deviation, total number of patients in each trial arm; treatment differences and standard error 
of the differences; where treatment 1 is a placebo and treatments 2-5 are active drugs. 
Study Treatment y sd n diff se(diff) 
1 1 -1.22 3.7 54 
-0.31 0.668 3 -1.53 4.28 95 
2 1 -0.7 3.7 172 
-1.7 0.383 2 -2.4 3.4 173 
3 1 -0.3 4.4 76   
2 -2.6 4.3 71 -2.3 0.718 
4 -1.2 4.3 81 -0.9 0.695 
4 3 -0.24 3 128 
-0.35 0.442 4 -0.59 3 72 
5 3 -0.73 3 80 
0.55 0.555 4 -0.18 3 46 
6 4 -2.2 2.31 137 
-0.3 0.274 5 -2.5 2.18 131 
7 4 -1.8 2.48 154 
-0.3 0.320 5 -2.1 2.99 143 
 
 
Figure A5 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of 
treatments which have been directly compared in randomised trials. The numbers on the lines indicate 
the numbers of trials making that comparison and the numbers by the treatment names are the treatment 
codes used in the modelling. 
 
The model for this type of data is outlined in Section 3.4. The WinBUGS code for random 
effects is given in program 5(a) and the fixed effects code is given in program 5(b).   
  
Treatment 5
Placebo
(Treatment 1)
Treatment 3
Treatment 4
Treatment 2
2
1
1
2
1
2
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Program 5(a):  Normal likelihood, identity link, Random Effects (Parkinson’s example) 
# Normal likelihood, identity link 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns){    #   LOOP THROUGH STUDIES 
    w[i,1] <- 0    # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0    # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)    # calculate variances 
        prec[i,k] <- 1/var[i,k]    # set precisions 
        y[i,k] ~ dnorm(theta[i,k],prec[i,k])  # normal likelihood 
        theta[i,k] <- mu[i] + delta[i,k]  # model for linear predictor 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]    #Deviance contribution 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])  #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {    # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])  # trial-specific LOR distributions 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]    # mean of treat effects distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k   # precision of treat effects distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)   # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])   #Total Residual Deviance 
d[1]<-0      # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
sd ~ dunif(0,5)    # vague prior for between-trial SD.  
tau <- pow(sd,-2)     # between-trial precision = (1/between-trial variance) 
}      # *** PROGRAM ENDS  
 
Additional code to monitor all treatment contrasts and rank treatments can be added as 
before. Given values for the mean, -0.73, and precision, 21, of the outcome on Treatment 1, 
from external sources, absolute effects, and the absolute treatment effect, could be monitored 
by adding the following code: 
 
A ~ dnorm(-.73,21) 
for (k in 1:nt) { T[k] <- A + d[k]  } 
 
The maximum number of arms is 3, so 3 vectors are needed for the treatment indicators, t[,1] 
t[,2], t[,3]; the continuous outcomes y[,] ; and their standard errors se[,] ; and finally the number of 
arms, na[]. 
# Data (Parkinson’s example) 
list(ns=7, nt=5) 
 
t[,1] t[,2] t[,3] y[,1] y[,2] y[,3] se[,1] se[,2] se[,3] na[] 
1 3 NA -1.22 -1.53 NA 0.504 0.439 NA 2 
1 2 NA -0.7 -2.4 NA 0.282 0.258 NA 2 
1 2 4 -0.3 -2.6 -1.2 0.505 0.510 0.478 3 
3 4 NA -0.24 -0.59 NA 0.265 0.354 NA 2 
3 4 NA -0.73 -0.18 NA 0.335 0.442 NA 2 
4 5 NA -2.2 -2.5 NA 0.197 0.190 NA 2 
4 5 NA -1.8 -2.1 NA 0.200 0.250 NA 2 
END 
81 
 
 
# Initial Values  
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d=c( NA, 0,0,0,0), sd=1, mu=c(0, 0, 0, 0, 0,    0, 0)) 
#chain 2 
list(d=c( NA, -1,-3,-1,1), sd=4, mu=c(-3, -3, -3, -3, -3,    -3, -3)) 
#chain 3 
list(d=c( NA, 2,2,2,2), sd=2, mu=c(-3, 5, -1, -3, 7,    -3, -4)) 
Program 5(b):  Normal likelihood, identity link, Fixed Effects (Parkinson’s example) 
# Normal likelihood, identity link 
# Fixed effects model for multi-arm trials 
model{       # *** PROGRAM STARTS 
for(i in 1:ns){     #   LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)      # vague priors for all trial baselines 
    for (k in 1:na[i]) {     #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)     # calculate variances 
        prec[i,k] <- 1/var[i,k]      # set precisions 
        y[i,k] ~ dnorm(theta[i,k],prec[i,k])    # normal likelihood 
        theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]]    # model for linear predictor 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]    #Deviance contribution 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])     #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])     #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }    # vague priors for treatment effects 
}         # *** PROGRAM ENDS  
 
# Initial Values  
#chain 1 
list(d=c( NA, 0,0,0,0), mu=c(0, 0, 0, 0, 0,    0, 0)) 
#chain 2 
list(d=c( NA, -1,-3,-1,1), mu=c(-3, -3, -3, -3, -3,    -3, -3)) 
#chain 3 
list(d=c( NA, 2,2,2,2), mu=c(-3, 5, -1, -3, 7,    -3, -4)) 
RESULTS 
Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000) are presented in 
Table A9. The random and fixed effects model both fit the data well, and since the random 
effects model has a higher DIC (due to having a higher effective number of parameters) the 
FE model should be preferred. The difference in mean of symptoms for each of the 
treatments compared to placebo and the absolute mean reduction in symptoms (assuming a 
baseline treatment effect as detailed above) are given in Table A9. 
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Table A9 Parkinson example: posterior mean, standard deviation (sd), median and 95% Credible 
interval (CrI) for both the fixed and random effects models for the treatment effects of Treatments 2 to 5 
(d12 to d15) relative to Placebo, absolute effects of Placebo (T1) and treatments 2 to 5 (T2 to T5), 
heterogeneity parameter τ and model fit statistics for different data types. 
 FE model RE model 
 mean sd median CrI mean sd median CrI 
 Arm-level data: Example 5 
d12 -1.81 0.33 -1.81 (-2.46,-1.16) -1.85 0.54 -1.84 (-2.91,-0.85) 
d13 -0.47 0.49 -0.47 (-1.43,0.49) -0.50 0.66 -0.50 (-1.78,0.75) 
d14 -0.52 0.48 -0.52 (-1.46,0.43) -0.53 0.65 -0.53 (-1.77,0.71) 
d15 -0.82 0.52 -0.82 (-1.84,0.22) -0.83 0.80 -0.83 (-2.35,0.69) 
T1 -0.73 0.22 -0.73 (-1.16,-0.30) -0.73 0.22 -0.73 (-1.16,-0.30) 
T2 -2.54 0.40 -2.54 (-3.32,-1.76) -2.58 0.58 -2.57 (-3.72,-1.50) 
T3 -1.21 0.53 -1.20 (-2.25,-0.15) -1.23 0.70 -1.23 (-2.57,0.10) 
T4 -1.25 0.53 -1.25 (-2.28,-0.21) -1.26 0.69 -1.26 (-2.57,0.05) 
T5 -1.55 0.57 -1.55 (-2.66,-0.43) -1.57 0.83 -1.56 (-3.14,0.02) 
τ - - - - 0.40 0.43 0.28 (0.01,1.55) 
resD * 13.3    13.6    
pD 11.0    12.4    
DIC 24.3    26.0    
 Trial-level data (differences): Example 7 
d12 -1.81 0.33 -1.81 (-2.47,-1.16) -1.85 0.54 -1.84 (-2.92,-0.84) 
d13 -0.48 0.49 -0.48 (-1.43,0.47) -0.50 0.66 -0.49 (-1.79,0.75) 
d14 -0.52 0.48 -0.52 (-1.46,0.42) -0.53 0.65 -0.53 (-1.79,0.72) 
d15 -0.82 0.52 -0.82 (-1.84,0.20) -0.83 0.81 -0.83 (-2.38,0.69) 
T1 -0.73 0.22 -0.73 (-1.16,-0.30) -0.73 0.22 -0.73 (-1.16,-0.30) 
T2 -2.54 0.40 -2.54 (-3.33,-1.76) -2.58 0.58 -2.57 (-3.72,-1.49) 
T3 -1.21 0.53 -1.21 (-2.25,-0.17) -1.23 0.70 -1.22 (-2.59,0.10) 
T4 -1.25 0.53 -1.25 (-2.28,-0.22) -1.26 0.69 -1.26 (-2.59,0.06) 
T5 -1.55 0.56 -1.55 (-2.66,-0.44) -1.56 0.83 -1.56 (-3.17,0.01) 
τ     0.41 0.44 0.28 (0.01,1.56) 
resD † 6.3    6.6    
pD 4.0    5.5    
DIC 10.3    12.1    
 Arm and Trial-level data (shared parameter model): Example 8 
d12 -1.81 0.33 -1.81 (-2.46,-1.16) -1.85 0.54 -1.83 (-2.91,-0.86) 
d13 -0.48 0.49 -0.48 (-1.43,0.48) -0.51 0.66 -0.50 (-1.79,0.75) 
d14 -0.52 0.48 -0.52 (-1.47,0.41) -0.54 0.65 -0.54 (-1.78,0.70) 
d15 -0.82 0.52 -0.82 (-1.85,0.20) -0.84 0.80 -0.84 (-2.35,0.69) 
T1 -0.73 0.22 -0.73 (-1.16,-0.30) -0.73 0.22 -0.73 (-1.16,-0.30) 
T2 -2.54 0.40 -2.54 (-3.32,-1.77) -2.57 0.58 -2.57 (-3.71,-1.49) 
T3 -1.21 0.53 -1.21 (-2.25,-0.17) -1.23 0.70 -1.23 (-2.58,0.09) 
T4 -1.26 0.53 -1.25 (-2.29,-0.23) -1.27 0.68 -1.27 (-2.58,0.05) 
T5 -1.56 0.57 -1.56 (-2.67,-0.45) -1.57 0.83 -1.57 (-3.14,0.02) 
τ     0.40 0.43 0.28 (0.01,1.53) 
resD ‡ 9.3    9.6    
pD 7.0    8.5    
DIC 16.3    18.1    
* compare to 15 data points; † compare to 8 data points; ‡ compare to 11 data points   
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EXAMPLE 6. PSORIASIS 
In an HTA report to evaluate the effectiveness of treatments for moderate to severe chronic 
plaque psoriasis,52 16 trials, comparing 8 treatments were identified: Supportive care (coded 
1); Etanercept 25 mg (2); Etanercept 50 mg (3); Efalizumab (4); Ciclosporin (5); Fumaderm 
(6); Infliximab (7) and Methotrexate (8). The network diagram is presented in Figure A6. 
Each trial reported the number of patients in mutually exclusive categories representing the 
percentage improvement in symptoms as measured by the PASI score. Different trials 
reported on different categories defining 3 cut-points, 50, 75 and 90% improvement, in 
addition to the scale’s lower and upper bounds (0 and 100% improvement, respectively). In 
the code below, we define: C=1 representing 0% improvement (the scale’s lower bound); 
C=2 representing 50% improvement; C=3 representing 75% improvement; and C=4 
representing 90% improvement. The data is presented in Table A10.  
 
Figure A6 Psoriasis network: each edge represents a treatment, connecting lines indicate pairs of 
treatments which have been directly compared in randomised trials. The numbers on the lines indicate 
the numbers of trials making that comparison and the numbers by the treatment names are the treatment 
codes used in the modelling. One trial compared two arms of Ciclosporin with Placebo and another 
compared two arms of Infliximab with placebo – these comparisons are not represented in the network. 
 
The model for this type of data is outlined in Section 3.6. The likelihood contribution of each 
trial is multinomial and this can be used to model the data directly in WinBUGS. However, 
since the reported categories are different in different studies and overlap, it is helpful to re-
write the multinomial likelihood as a series of conditional Binomials.  
Ciclosporin
(5)
Placebo
(1)
Etanercept 50 mg
(3)
Efalizumab
(4)
Etanercept 25 mg
(2)
Fumaderm
(6)
3
Methotrexate
(8)
Infliximab
(7)
2
5
1
3
2
1
5
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So, for a trial i reporting the number of patients rikj in category j=1,…,Ji, we can write 
rikj ~ Binomial(qikj, Nikj)  j=1,…,Ji-1 
where  
 
 
 
 
1
2
1
  Pr PASI score in category 1 of trial 
  Pr PASI score in category 2 of trial  |  not in category 1
  Pr PASI score in category  of trial  |  not in categories 1, 2, , 1
1 i
i
ik
ik
ikj
J
ikJ ikjj
q i
q i
q j i j
q q




  
 
1

 
and 1
1
j
ikj ik ikuu
N n r

  . 
Noting that the lower and upper bounds of each mutually exclusive category are defined by 
the cut-points above and the scale’s lower and upper bounds, for arm k of trial i we can define 
qikj as the probability of belonging to category j, in arm k of trial i, 
qikj = Pr(PASI score in category j) = Pr(Lj< PASI score < Uj) 
where Lj and Uj define the lower and upper bounds of the interval defining category j. So, for 
example, for arm 1 of study 1 in Table A10 category 1 is 0-50% improvement so 
q111 = Pr(having less than 50% improvement in PASI score) = Pr(0< PASI score < 50). 
Letting pikc denote the probability of achieving a PASI score of at least c, in arm k of trial i, 
for c=50, 75, 90 we model 
ikc = Pr(PASI score > c) = (θik+zc) 
where θik is the linear predictor and  is the standard normal cumulative distribution 
function. Cut- points z50, z75 and z90 have been coded z1, z2 and z3, respectively, in the code 
below. We set z1=0 and give non-informative priors to z2 and z3. 
The terms zc can be thought of as the distance on the standard normal scale between the 
category boundaries. The “fixed effect” model above assumes that these distances are the 
same in every trial and for every treatment. An alternative might be that they differ between 
trials, but that within a trial the distances between categories are the same. This leads us to a 
“random effects” model in which for each trial i, zic varies around a mean  
 2~ ( , )ic c zz N v  . 
The mean and variance are then given vague priors in the usual way. One interpretation of 
this model, which can be used with a Fixed or Random treatment effects, is that there may be 
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differences between trials in the way that the underlying symptoms are scored, in this case on 
the PASI scale. It can be shown that, for j=1,…,Ji-1 
 11
Pr(PASI )
1 1
Pr(PASI )
j
j
ikCj
ikj
j ikC
C
q
C


   

 
with Cj and Cj+1 representing the lower and upper bounds of the interval defining category j, 
respectively. Using these relationships simplifies the code and makes it general for any 
number of categories and cut-off points.  
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Table A10 Psoriasis example: study names, treatments compared, total number of patients with different percentage improvement and total number of patients in 
each trial arm, where Supportive Care = treatment 1, Etanercept 25mg = 2, Etanercept 50 mg = 3, Efalizumab = 4, Ciclosporin = 5, Fumaderm = 6, Infliximab = 7, 
Methotreaxate = 8.52 
    
Outcomes presented in 
arm 1 for each category 
total number 
of patients in 
arm 1 
Outcomes presented in arm 2 
for each category 
total number 
of patients in 
arm 2 
Outcomes presented in 
arm 3 for each category 
total number 
of patients in 
arm 3 
    
Trials presenting outcomes in 4 categories 
 
arm 1 arm 2 arm 3 
0-50 50–75 75–90 90-100 n[,1] 0-50 50–75 75–90 90-100 n[,2] 0-50 50–75 75–90 
90-
100 n[,3] Trial t[,1] t[,2] t[,3] 
1.Elewski 2004 1 2 3 175 12 5 1 193 70 59 46 21 196 44 54 56 40 194 
2.Gottlieb 2003 1 2 
 
49 5 1 0 55 17 23 11 6 57 
     3.Lebwohl 2003 1 4 
 
103 13 5 1 122 112 68 42 10 232 
     4.Leonardi 2003 1 2 3 142 18 5 1 166 68 39 36 19 162 43 40 45 36 164 
    Trials presenting outcomes in 3 categories 
 
t[,1] t[,2] t[,3] 0-50 50–75 75-100 
  
0-50 50–75 75-100 
  
0-50 50–75 75-100 
  5.Gordon 2003 1 4 
 
161 18 8 
 
187 153 118 98 
 
369 
         Trials presenting outcomes in 2 categories (PASI 50) 
Trial t[,1] t[,2] t[,3] 0-50 50-100
   
0-50 50-100 
   
0-50 50-100 
   6.ACD2058g 1 4 
 
145 25 
  
170 63 99 
  
162 
     7.ACD2600g 1 4 
 
230 33 
  
263 216 234 
  
450 
     8.Guenther 1991 1 5 
 
10 1 
  
11 0 12 
  
12 
     9.IMP24011 1 4 
 
226 38 
  
264 245 284 
  
529 
         Trials presenting outcomes in 2 categories (PASI 75) 
Trial t[,1] t[,2] t[,3] 0-75 75-100
   
0-75 75-100 
   
0-75 75-100 
   10.Altmeyer 1994 1 6 
 
50 1 
  
51 37 12 
  
49   
   11.Chaudari 2001 1 7 
 
9 2 
  
11 2 9 
  
11   
   12.Ellis 1991 1 5 5 25 0 
  
25 16 9 
  
25 7 13 
  
20 
13.Gottlieb 2004 1 7 7 48 3 
  
51 28 71 
  
99 12 87 
  
99 
14.Heydendael 2003 5 8 
 
12 30 
  
42 17 26 
  
43   
   15.Meffert 1997 1 5 
 
41 2 
  
43 37 4 
  
41   
   16.Van Joost 1988 1 5 
 
10 0 
  
10 3 7 
  
10   
   
87 
 
The WinBUGS code for random effects is given in program 6(a) and the fixed effects code is 
given in program 6(b).  
Program 6(a): Conditional Binomial likelihood, probit link, Random Effects (Psoriasis 
example) 
# Binomial likelihood, probit link (different categories) 
# Random effects model for multi-arm trials 
model{     # *** PROGRAM STARTS 
for(i in 1:ns){     #   LOOP THROUGH STUDIES 
    w[i,1] <- 0        # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0                # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
    for (k in 1:na[i]) {                # LOOP THROUGH ARMS 
        p[i,k,1] <- 1                   # Pr(PASI >0) 
        q[i,k,nc[i]] <- 1 - sum(q[i,k,1:(nc[i]-1)]) # Pr(being in last category)=1-sum of all other probs, collected in p.aux 
        for (j in 1:nc[i]-1) {        # LOOP THROUGH CATEGORIES 
            r[i,k,j] ~ dbin(q[i,k,j],n[i,k,j])   # binomial likelihood 
            q[i,k,j] <- 1-(p[i,k,C[i,j+1]]/p[i,k,C[i,j]]) # conditional probabilities 
             theta[i,k,j] <- mu[i] + delta[i,k] + z[j]  # linear predictor 
            rhat[i,k,j] <-  q[i,k,j] * n[i,k,j]    # predicted number events  
            dv[i,k,j] <- 2 * (r[i,k,j]*(log(r[i,k,j])-log(rhat[i,k,j]))  #Deviance contribution of each category 
    +(n[i,k,j]-r[i,k,j])*(log(n[i,k,j]-r[i,k,j]) - log(n[i,k,j]-rhat[i,k,j]))) 
          } 
        dev[i,k] <- sum(dv[i,k,1:nc[i]-1])   # deviance contribution of each arm 
        for (j in 2:nc[i])  {   # LOOP THROUGH CATEGORIES 
            p[i,k,C[i,j]] <- 1 - phi.adj[i,k,j]     # link function 
# adjust link function phi(x) for extreme values that can give numerical errors 
# when x< -5, phi(x)=0, when x> 5, phi(x)=1 
            phi.adj[i,k,j] <- step(5+theta[i,k,j-1]) 
                   * (step(theta[i,k,j-1]-5)  
                      + step(5-theta[i,k,j-1])*phi(theta[i,k,j-1]) ) 
          } 
      } 
    for (k in 2:na[i]) {            # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]  # mean of LHR distributions, with multi-arm trial correction 
        taud[i,k] <- tau *2*(k-1)/k   # precision of LHR distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment, multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)  # cumulative adjustment for multi-arm trials 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])         #  summed residual deviance contribution for this trial 
  }    
z[1] <- 0                          # set z50=0 
z[2] ~ dunif(0,5)                  # prior for z75 
z90aux ~ dunif(0,5)                # prior for z90 is U(z75, z75+5) 
z[3] <- z[2] + z90aux 
totresdev <- sum(resdev[])        #Total Residual Deviance 
d[1] <- 0           # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
sd ~ dunif(0,5)                   # vague prior for between-trial SD 
tau <- pow(sd,-2)        # between-trial precision = (1/between-trial variance) 
}                                        # *** PROGRAM ENDS 
 
Additional code to monitor all treatment contrasts and rank treatments can be added as 
before. Given values for the mean, 1.097, and precision, 123, of the effects on Treatment 1 on 
the probit scale, from external sources, absolute effects, and absolute probabilities T[j,k] of 
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having over 50, 75 or 90% improvement (j=1,2,3 respectively) on treatment k, could be 
monitored as follows: 
 
A ~ dnorm(1.097,123) 
# calculate prob of achieving PASI50,75,90 on treat k 
for (k in 1:nt) {  
    for (j in 1:3) {  T[j,k] <- 1 - phi(A + d[k] + z[j]) } 
  } 
 
The data structure again consists of a list specifying the number of treatments nt and number 
of studies ns, with the main body of data in a vector format. Both data components need to be 
loaded into WinBUGS for the program to run. Three columns are required for each arm 
variable since there are four three-arm trials: t[,1], t[,2] and t[,3] are the treatment codes; na[] 
represents the number of arms and nc[] the number of cut-offs in that trial; C[,1], C[,2], C[,3], C[,4] 
represent the cut-offs used to define the categories reported in each trial – four columns are 
needed as the maximum number of cut-offs given in a trial is four – these cut-offs are coded 1 
to 4 as described above; then r[,k,j] the number of events for the k-th treatment, in category j 
given the number of events in categories 1 to j-1; then n[,k,1] represents the total number of 
individuals in trial arm k, n[,k,2] represents the total number of individuals in trial arm k, which 
were not in category 1 of that trial and n[,k,3] represents the total number of individuals in trial 
arm k, which were not in categories 1 or 2 of that trial. So, for example, for the first trial in 
Table A10, Elewski 2004, 193 patients were included in arm 1 of the trial. These patients 
were split between the four categories as follows: 175 out of 193 patients had between 0 and 
50% improvement, leaving 18 patients who could belong to any of the other categories, thus 
r111=173, n111=193; 12 out of 18 patients had between 50 and 75% improvement, leaving 6 
patients who could belong to any of the other categories, thus r112=12, n112=193-175=18; 5 
out of 6 patients had between 75 and 90% improvement, leaving 1 patient (who necessarily 
had over 90% improvement), thus r113=5, n112=18-12=6. All other nikj were similarly 
calculated for the other trials. 
 
# Data (Psoriasis example) 
list(ns=16, nt=8)    
 
t[,1] t[,2] t[,3] na[] nc[] C[,1] C[,2] C[,3] C[,4] r[,1,1] r[,1,2] r[,1,3]
 n[,1,1] n[,1,2] n[,1,3] r[,2,1] r[,2,2] r[,2,3] n[,2,1] n[,2,2] n[,2,3] r[,3,1] r[,3,2]
 r[,3,3] r[,3,4] n[,3,1] n[,3,2] n[,3,3] 
1 2 3 3 4 1 2 3 4 175 12 5 193
 18 6 70 59 46 196 126 67 44 54 56 40
 194 150 94 
1 2 NA 2 4 1 2 3 4 49 5 1 55
 6 1 17 23 11 57 40 17 NA NA NA NA
 NA NA NA 
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1 4 NA 2 4 1 2 3 4 103 13 5 122
 19 6 112 68 42 232 120 52 NA NA NA NA
 NA NA NA 
1 2 3 3 4 1 2 3 4 142 18 5 166
 24 6 68 39 36 162 94 55 43 40 45 36
 164 121 76 
1 4 NA 2 3 1 2 3 NA 161 18 8 187
 26 8 153 118 98 369 216 98 NA NA NA NA
 NA NA NA 
1 4 NA 2 2 1 2 NA NA 145 25 NA 170
 25 0 63 99 NA 162 99 0 NA NA NA NA
 NA NA NA 
1 4 NA 2 2 1 2 NA NA 230 33 NA 263
 33 0 216 234 NA 450 234 0 NA NA NA NA
 NA NA NA 
1 5 NA 2 2 1 2 NA NA 10 1 NA 11
 1 0 0 12 NA 12 12 0 NA NA NA NA
 NA NA NA 
1 4 NA 2 2 1 2 NA NA 226 38 NA 264
 38 0 245 284 NA 529 284 0 NA NA NA NA
 NA NA NA 
1 6 NA 2 2 1 3 NA NA 50 1 NA 51
 50 0 37 12 NA 49 37 0 NA NA NA NA
 NA NA NA 
1 7 NA 2 2 1 3 NA NA 9 2 NA 11
 9 0 2 9 NA 11 2 0 NA NA NA NA
 NA NA NA 
1 5 5 3 2 1 3 NA NA 25 0 NA 25
 25 0 16 9 NA 25 16 0 7 13 NA NA
 20 7 NA 
1 7 7 3 2 1 3 NA NA 48 3 NA 51
 48 0 28 71 NA 99 28 0 12 87 NA NA
 99 12 NA 
5 8 NA 2 2 1 3 NA NA 12 30 NA 42
 12 0 17 26 NA 43 17 0 NA NA NA NA
 NA NA NA 
1 5 NA 2 2 1 3 NA NA 41 2 NA 43
 41 0 37 4 NA 41 37 0 NA NA NA NA
 NA NA NA 
1 5 NA 2 2 1 3 NA NA 10 0 NA 10
 10 0 3 7 NA 10 3 0 NA NA NA NA
 NA NA NA 
END 
 
# Initial Values  
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d = c(NA,0,0,0,0,0,0,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 1,   z=c(NA, 0.66,NA), z90aux =1.28) 
 
#chain 2 
list(d = c(NA,0,0,1,0,0,2,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 1.5,   z=c(NA, 0.5,NA), z90aux=1 ) 
 
#chain 3 
list(d = c(NA,1,1,1,1,1,1,1), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 3,   z=c(NA, 0.1,NA) , z90aux=2) 
 
The parameters to monitor are the same as in Example 1. We may in addition want to monitor 
node z to obtain the posterior summaries for the different cut-off points. 
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Program 6(b): Conditional Binomial likelihood, probit link, Fixed Effects (Psoriasis 
example) 
# Binomial likelihood, probit link (different categories) 
# Fixed effects model for multi-arm trials 
model{                                  # *** PROGRAM STARTS 
for(i in 1:ns){                         #   LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)   # vague priors for all trial baselines 
    for (k in 1:na[i]) {                # LOOP THROUGH ARMS 
        p[i,k,1] <- 1                   # Pr(PASI >0) 
        q[i,k,nc[i]] <- 1 - sum(q[i,k,1:(nc[i]-1)]) # Pr(being in last category)=1-sum of all other probs, collected in p.aux 
        for (j in 1:nc[i]-1) {          # LOOP THROUGH CATEGORIES 
            r[i,k,j] ~ dbin(q[i,k,j],n[i,k,j])   # binomial likelihood 
            q[i,k,j] <- 1-(p[i,k,C[i,j+1]]/p[i,k,C[i,j]]) # conditional probabilities 
            theta[i,k,j] <- mu[i] + d[t[i,k]] + d[t[i,1]] + z[j] # linear predictor 
            rhat[i,k,j] <-  q[i,k,j] * n[i,k,j]    # predicted number events  
            dv[i,k,j] <- 2 * (r[i,k,j]*(log(r[i,k,j])-log(rhat[i,k,j]))  #Deviance contribution of each category 
    +(n[i,k,j]-r[i,k,j])*(log(n[i,k,j]-r[i,k,j]) - log(n[i,k,j]-rhat[i,k,j]))) 
          } 
        dev[i,k] <- sum(dv[i,k,1:nc[i]-1])   # deviance contribution of each arm 
        for (j in 2:nc[i])  {   # LOOP THROUGH CATEGORIES 
            p[i,k,C[i,j]] <- 1 - phi.adj[i,k,j]     # link function 
# adjust phi(x) for extreme values that can give numerical errors 
# when x< -5, phi(x)=0, when x> 5, phi(x)=1 
            phi.adj[i,k,j] <- step(5+theta[i,k,j-1]) 
                   * (step(theta[i,k,j-1]-5)  
                      + step(5-theta[i,k,j-1])*phi(theta[i,k,j-1]) ) 
          } 
      } 
    resdev[i] <- sum(dev[i,1:na[i]])         #  summed residual deviance contribution for this trial 
  }    
z[1] <- 0                          # set z50=0 
z[2] ~ dunif(0,5)                  # prior for z75 
z90aux ~ dunif(0,5)                # prior for z90 is U(z75, z75+5) 
z[3] <- z[2] + z90aux 
totresdev <- sum(resdev[])        #Total Residual Deviance 
d[1] <- 0           # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
}                                        # *** PROGRAM ENDS  
 
# Initial Values  
#chain 1 
list(d = c(NA,0,0,0,0,0,0,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  z=c(NA, 0.66,NA), z90aux =1.28) 
 
#chain 2 
list(d = c(NA,0,0,1,0,0,2,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  z=c(NA, 0.5,NA), z90aux=1 ) 
 
#chain 3 
list(d = c(NA,1,1,1,1,1,1,1), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  z=c(NA, 0.1,NA) , z90aux=2) 
RESULTS 
Results for the fixed and random effects models are presented in Table A11 (results based on 
3 chains: 100,000 iterations after a burn-in of 40,000 and 50,000 for the FE and RE models, 
respectively). From the residual deviance and DIC we conclude that the random effects 
model should be preferred as it is a better fit to the data and has a smaller DIC. The treatment 
effects relative to Supportive care (treatment 1) are all below zero which suggests that all 
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treatments are better than Supportive care at increase the probability of a reduction in 
symptoms on the probit scale. The absolute probabilities of achieving a reduction on at least 
50, 75 or 90% in symptoms show that, for example, there is on average 0% probability of 
achieving at least a 90% reduction in symptoms with Supportive care, but this probability is 
on average 37% with Infliximab. 
A model which assumes the cut-points differ between trials and come from a common 
distribution was also fitted and gave very similar results. 
Table A11 Psoriasis example: posterior mean, standard deviation (sd), median and 95% Credible interval 
(CrI) for both the fixed and random effects models for the treatment effects, on the probit scale, of 
Etanercept 25 mg (d12), Etanercept 50 mg (d13), Efalizumab (d14), Ciclosporin (d15) , Fumaderm (d16) , 
Infliximab (d17), and Methotrexate (d18) relative to Supportive Care; absolute probabilities of achieving at 
least 50, 70 or 90% relief in symptoms for each treatment; heterogeneity parameter τ and model fit 
statistics. 
 
FE model RE model 
 mean sd median CrI mean sd median CrI 
d12 -1.51 0.10 -1.51 (-1.70,-1.33) -1.53 0.24 -1.53 (-2.04,-1.04) 
d13 -1.91 0.10 -1.91 (-2.11,-1.72) -1.92 0.28 -1.92 (-2.50,-1.35) 
d14 -1.19 0.06 -1.19 (-1.30,-1.08) -1.19 0.18 -1.19 (-1.56,-0.81) 
d15 -1.94 0.34 -1.92 (-2.64,-1.31) -2.03 0.43 -1.99 (-3.00,-1.30) 
d16 -1.50 0.49 -1.46 (-2.59,-0.64) -1.48 0.61 -1.45 (-2.77,-0.34) 
d17 -2.34 0.27 -2.33 (-2.87,-1.83) -2.32 0.38 -2.33 (-3.07,-1.56) 
d18 -1.63 0.44 -1.62 (-2.53,-0.80) -1.72 0.64 -1.68 (-3.12,-0.56) 
τ - - - - 0.30 0.23 0.26 (0.01,0.87) 
Probability of achieving at least 50% relief in symptoms (PASI50) 
Supportive Care  0.14 0.02 0.14 (0.10,0.18) 0.14 0.02 0.14 (0.10,0.18) 
Etanercept 25 mg 0.66 0.05 0.66 (0.56,0.75) 0.66 0.09 0.67 (0.47,0.83) 
Etanercept 50 mg 0.79 0.04 0.79 (0.71,0.86) 0.79 0.08 0.79 (0.59,0.92) 
Efalizumab 0.54 0.04 0.54 (0.45,0.62) 0.54 0.08 0.54 (0.38,0.69) 
Ciclosporin 0.79 0.10 0.80 (0.58,0.94) 0.80 0.11 0.81 (0.57,0.97) 
Fumaderm 0.64 0.16 0.64 (0.32,0.93) 0.63 0.19 0.64 (0.22,0.95) 
Infliximab 0.88 0.05 0.89 (0.76,0.96) 0.87 0.08 0.89 (0.67,0.98) 
Methotrexate 0.69 0.15 0.70 (0.38,0.93) 0.70 0.18 0.72 (0.29,0.98) 
Probability of achieving at least 75% relief in symptoms (PASI75) 
Supportive Care  0.03 0.01 0.03 (0.02,0.05) 0.03 0.01 0.03 (0.02,0.05) 
Etanercept 25 mg 0.37 0.05 0.37 (0.28,0.47) 0.38 0.09 0.37 (0.20,0.58) 
Etanercept 50 mg 0.52 0.05 0.52 (0.42,0.63) 0.53 0.11 0.53 (0.30,0.75) 
Efalizumab 0.25 0.03 0.25 (0.19,0.33) 0.26 0.06 0.25 (0.14,0.40) 
Ciclosporin 0.53 0.13 0.53 (0.29,0.79) 0.56 0.15 0.56 (0.28,0.88) 
Fumaderm 0.37 0.17 0.35 (0.11,0.77) 0.37 0.20 0.34 (0.06,0.82) 
Infliximab 0.68 0.10 0.68 (0.48,0.85) 0.67 0.13 0.68 (0.38,0.89) 
Methotrexate 0.42 0.16 0.41 (0.14,0.76) 0.45 0.21 0.43 (0.10,0.90) 
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Probability of achieving at least 90% relief in symptoms (PASI90) 
Supportive Care  0.00 0.00 0.00 (0.00,0.01) 0.00 0.00 0.00 (0.00,0.01) 
Etanercept 25 mg 0.12 0.03 0.12 (0.08,0.19) 0.13 0.06 0.13 (0.05,0.27) 
Etanercept 50 mg 0.22 0.04 0.22 (0.15,0.31) 0.23 0.09 0.22 (0.09,0.44) 
Efalizumab 0.07 0.02 0.07 (0.04,0.10) 0.07 0.03 0.07 (0.03,0.14) 
Ciclosporin 0.24 0.11 0.22 (0.08,0.50) 0.27 0.14 0.25 (0.08,0.63) 
Fumaderm 0.15 0.12 0.11 (0.02,0.47) 0.15 0.14 0.11 (0.01,0.54) 
Infliximab 0.37 0.10 0.36 (0.19,0.59) 0.37 0.14 0.36 (0.13,0.66) 
Methotrexate 0.17 0.11 0.15 (0.03,0.45) 0.21 0.17 0.16 (0.02,0.68) 
resD * 74.5    
62.7 
   
pD 25.0    
33.2 
   
DIC 99.4    
96.0 
   
* compare with 58 data points 
 
EXAMPLE 7. PARKINSON’S DIFFERENCE (TREATMENT DIFFERENCES AS 
DATA) 
We now assume that the data available for the Parkinson’s example were not the mean off-
time reduction for patients in each arm of the trial, but rather the differences in off-time 
reduction, and their standard errors, between the intervention and control arms for each trial, 
as presented in the last two columns of Table A8. The data available are therefore the 
differences, their standard errors and the treatments compared in each trial, coded as before. 
Random and fixed effects models were fitted, as outlined in Section 3.4. The code is given 
below. As explained in Section 5.1 the coding for the likelihood has been modified to allow 
for the 3-arm trial. This requires users to set up the data file with all two-arm trials first, then 
3-arm trials, then – if any were present – 4-arm trials, and so on. 
Program 7(a):  Normal likelihood, identity link, treatment differences, Random Effects 
(Parkinson’s Differences) 
# Normal likelihood, identity link, trial-level data given as treatment differences 
# Random effects model for multi-arm trials 
model{     # *** PROGRAM STARTS 
for(i in 1:ns2) {    # LOOP THROUGH 2-ARM STUDIES 
    y[i,2] ~ dnorm(delta[i,2],prec[i,2])   # normal likelihood for 2-arm trials 
    resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution for trial i 
  } 
for(i in (ns2+1):(ns2+ns3)) {          # LOOP THROUGH 3-ARM STUDIES 
    for (k in 1:(na[i]-1)) {       # set variance-covariance matrix 
        for (j in 1:(na[i]-1)) {  Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)   } 
      } 
    Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,])  #Precision matrix 
# multivariate normal likelihood for 3-arm trials    
    y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])  
#Deviance contribution for trial i 
    for (k in 1:(na[i]-1)){     # multiply vector & matrix 
        ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)] 
        z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)]) 
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      } 
    resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)]) 
  } 
for(i in 1:(ns2+ns3)){     # LOOP THROUGH ALL STUDIES 
    w[i,1] <- 0        # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0                # treatment effect is zero for control arm 
    for (k in 2:na[i]) {                #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)     # calculate variances 
        prec[i,k] <- 1/var[i,k]         # set precisions 
      } 
    resdev[i] <- sum(dev[i,2:na[i]])         #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {    # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k])    # trial-specific treat effects distributions 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]   # mean of treat effects distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k    # precision of treat effects distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])   # adjustment for multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)  # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])              #Total Residual Deviance 
d[1]<-0           # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }  # vague priors for treatment effects 
sd ~ dunif(0,5)         # vague prior for between-trial SD 
tau <- pow(sd,-2)       # between-trial precision = (1/between-trial variance) 
}                                        # *** PROGRAM ENDS  
 
Additional code to monitor all treatment contrasts and rank treatments can be added as 
before. Given values for the mean, meanA=-0.73, and precision, precA=21, of the effects on 
Treatment 1, from external sources, absolute effects, could be monitored as follows: 
 
A ~ dnorm(meanA,precA) 
for (k in 1:nt) { T[k] <- A + d[k]  } 
 
If trials with four or more arms were included, a further multivariate normal likelihood 
statement would need to be added and the corresponding variance-covariance and precision 
matrices built (Sigma2 and Omega2, say). So, for example if ns4 4-arm trials were available, we 
would add the following lines of code to the above, taking care to change all the relevant 
loops to go through all trials: 
for(i in (ns2+ns3+1):(ns2+ns3+ns4)) {         # LOOP THROUGH 4-ARM STUDIES 
    for (k in 1:(na[i]-1)) {       # set variance-covariance matrix 
        for (j in 1:(na[i]-1)) {  Sigma2[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)   } 
      } 
    Omega2[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma2[i,,])  #Precision matrix 
# multivariate normal likelihood for 4-arm trials    
    y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega2[i,1:(na[i]-1),1:(na[i]-1)])  
  } 
 
If no multi-arm trials are included, the code simplifies to: 
# Normal likelihood, identity link, trial-level data given as treatment differences 
# Random effects model for two-arm trials 
model{     # *** PROGRAM STARTS 
for(i in 1:ns2) {    # LOOP THROUGH 2-ARM STUDIES 
    y[i,2] ~ dnorm(delta[i,2],prec[i,2])   # normal likelihood for 2-arm trials 
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    var[i,2] <- pow(se[i,2],2)      # calculate variances 
    prec[i,2] <- 1/var[i,2]         # set precisions 
    dev[i,2] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution 
    delta[i,2] ~ dnorm(md[i,2],tau)    # trial-specific treat effects distributions 
    md[i,2] <-  d[t[i,2]] - d[t[i,1]]     # mean of treat effects distributions 
  }    
totresdev <- sum(dev[,2])              #Total Residual Deviance 
d[1]<-0           # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }  # vague priors for treatment effects 
sd ~ dunif(0,5)         # vague prior for between-trial SD 
tau <- pow(sd,-2)       # between-trial precision = (1/between-trial variance) 
}                                        # *** PROGRAM ENDS  
 
The data structure is similar to that of Example 5 but we now have to specify the number of 
two-arm trials ns2 and the number of three-arm trials ns3.  The maximum number of arms is 3, 
so 3 vectors are needed for the treatment indicators, t[,1] t[,2], t[,3]; for a trial with 3 treatment 
arms, two treatment differences will be available, so 2 vectors of differences (the continuous 
outcomes) y[,]  and their standard errors se[,] are needed; and finally the number of arms, na[] 
and V[] the variance of the baseline treatment in that trial (needed to adjust for the correlation 
in multi-arm trials – note that this variable only need to have values assigned when there are 
multi-arm trials), with NA denoting a missing observation. Note that any three-arm trials need 
to appear at the end of the column format data. 
 
# Data (Parkinson’s example – trial-level data: treatment differences) 
list(ns2=6, ns3=1, nt=5)    
 
t[,1] t[,2] t[,3] y[,2] y[,3] se[,2] se[,3] na[]  V[] 
1 3 NA -0.31 NA 0.668089651 NA         2  NA 
1 2 NA -1.7 NA 0.382640605 NA     2  NA 
3 4 NA -0.35 NA 0.441941738 NA     2  NA 
3 4 NA 0.55 NA 0.555114559 NA     2  NA 
4 5 NA -0.3 NA 0.274276316 NA     2  NA 
4 5 NA -0.3 NA 0.320087245 NA     2  NA 
1 2 4 -2.3 -0.9 0.71774604           0.694988091   3  0.254736842 
END 
 
# Initial Values  
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d=c( NA, 0,0,0,0), sd=1) 
#chain 2 
list(d=c( NA, -1,-3,-1,1), sd=4) 
#chain 3 
list(d=c( NA, 2,2,2,2), sd=2) 
 
The parameters to monitor are the same as in Example 5. 
Program 7(b):  Normal likelihood, identity link, treatment differences, Fixed Effects 
(Parkinson’s Differences) 
# Normal likelihood, identity link, trial-level data given as treatment differences 
# Fixed effects model  
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model{     # *** PROGRAM STARTS 
for(i in 1:ns2) {     # LOOP THROUGH 2-ARM STUDIES 
    y[i,2] ~ dnorm(delta[i,2],prec[i,2])   # normal likelihood for 2-arm trials 
    resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution for trial i 
  } 
for(i in (ns2+1):(ns2+ns3)) {          # LOOP THROUGH MULTI-ARM STUDIES 
    for (k in 1:(na[i]-1)) {       # set variance-covariance matrix 
        for (j in 1:(na[i]-1)) {  Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)  } 
      } 
    Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,])  #Precision matrix 
# multivariate normal likelihood for 3-arm trials    
    y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])  
#Deviance contribution for trial i 
    for (k in 1:(na[i]-1)){     # multiply vector & matrix 
        ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)] 
        z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)]) 
      } 
    resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)]) 
  } 
for(i in 1:(ns2+ns3)){                        # LOOP THROUGH ALL STUDIES 
     for (k in 2:na[i]) {                #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)     # calculate variances 
        prec[i,k] <- 1/var[i,k]         # set precisions 
        delta[i,k] <-  d[t[i,k]] - d[t[i,1]] 
      } 
    resdev[i] <- sum(dev[i,2:na[i]])     #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])              #Total Residual Deviance 
d[1]<-0           # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }  # vague priors for treatment effects 
}      # *** PROGRAM ENDS   
 
# Initial Values  
#chain 1 
list(d=c( NA, 0,0,0,0)) 
#chain 2 
list(d=c( NA, -1,-3,-1,1)) 
#chain 3 
list(d=c( NA, 2,2,2,2)) 
RESULTS 
Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000) are presented in 
Table A9 and are the same as the results obtained using the model in Example 5. 
 
EXAMPLE 8. PARKINSON’S SHARED PARAMETERS (MIXED TREATMENT 
DIFFERENCE AND ARM-LEVEL DATA) 
To illustrate a meta-analysis with a shared parameter model (Section 4) we will assume that 
the data available for the Parkinson’s example were the mean off-time reduction for patients 
in each arm of the trial for the first three trials, but only the differences between the 
intervention and control arms (and their standard errors) were available for the remaining 
trials (Table A8).   
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Random and fixed effects models were fitted. The code below consists of a combination of 
the code used in Example 5, for the arm-level data, and the code used in Example 7, for the 
trial level data. 
Program 8(a): Normal likelihood, identity link, shared parameter model, Random 
Effects (Parkinson’s shared parameters) 
# Normal likelihood, identity link, Arm and Trial-level data (treatment differences) 
# Random effects model for multi-arm trials 
model{      # *** PROGRAM STARTS 
for(i in 1:ns.a){     # LOOP THROUGH STUDIES WITH ARM DATA 
    w.a[i,1] <- 0     # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0       # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)      # vague priors for all trial baselines 
    for (k in 1:na.a[i]) {    #  LOOP THROUGH ARMS 
        var.a[i,k] <- pow(se.a[i,k],2)    # calculate variances 
        prec.a[i,k] <- 1/var.a[i,k]     # set precisions 
        y.a[i,k] ~ dnorm(theta[i,k],prec.a[i,k])   # normal likelihood 
        theta[i,k] <- mu[i] + delta[i,k]     # model for linear predictor 
        dev[i,k] <- (y.a[i,k]-theta[i,k])*(y.a[i,k]-theta[i,k])*prec.a[i,k]    #Deviance contribution 
      } 
    resdev[i] <- sum(dev[i,1:na.a[i]])     #  summed residual deviance contribution for this trial 
    for (k in 2:na.a[i]) {      # LOOP THROUGH ARMS 
        delta[i,k] ~ dnorm(md[i,k],taud.a[i,k])  # trial-specific LOR distributions 
# mean of LOR distributions, with multi-arm trial correction 
        md[i,k] <-  d[t.a[i,k]] - d[t.a[i,1]] + sw.a[i,k]  
        taud.a[i,k] <- tau *2*(k-1)/k   # precision of LOR distributions (with multi-arm trial correction) 
        w.a[i,k] <- (delta[i,k] - d[t.a[i,k]] + d[t.a[i,1]])  # adjustment, multi-arm RCTs 
        sw.a[i,k] <- sum(w.a[i,1:k-1])/(k-1)   # cumulative adjustment for multi-arm trials 
      } 
  } 
for(i in 1:ns.t){     # LOOP THROUGH STUDIES WITH TRIAL DATA 
    w[i,1] <- 0       # adjustment for multi-arm trials is zero for control arm 
    delta[i+ns.a,1] <- 0      # treatment effect is zero for control arm 
    for (k in 2:na[i]) {     #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)     # calculate variances 
        prec[i,k] <- 1/var[i,k]     # set precisions 
        y[i,k] ~ dnorm(delta[i+ns.a,k],prec[i,k])   # normal likelihood 
        dev[i+ns.a,k] <- (y[i,k]-delta[i+ns.a,k])*  #Deviance contribution 
                         (y[i,k]-delta[i+ns.a,k])* prec[i,k] 
      } 
    resdev[i+ns.a] <- sum(dev[i+ns.a,2:na[i]])   #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {      # LOOP THROUGH ARMS 
        delta[i+ns.a,k] ~ dnorm(md[i+ns.a,k],taud[i,k])     # trial-specific LOR distributions 
        md[i+ns.a,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]   # mean of LOR distributions, with multi-arm trial correction 
        taud[i,k] <- tau *2*(k-1)/k    # precision of LOR distributions (with multi-arm trial correction) 
        w[i,k] <- (delta[i+ns.a,k] - d[t[i,k]] + d[t[i,1]])  # adjustment, multi-arm RCTs 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1)   # cumulative adjustment for multi-arm trials 
      } 
  }    
totresdev <- sum(resdev[])     #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
sd ~ dunif(0,5)       # vague prior for between-trial SD 
tau <- pow(sd,-2)      # between-trial precision = (1/between-trial variance) 
}        # *** PROGRAM ENDS  
 
Additional code to monitor all treatment contrasts, rank treatments and obtain absolute 
treatment effects can be added as before.  
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The data structure for this code consists of three parts. First, a list giving the number of 
studies with arm-level information, ns.a, the number of studies with trial-level information, 
ns.t, and the number of treatments, nt.  Two sections of column format data follow: one with 
the arm-level data, with the structure described for program 5(a), and another with the trial-
level data and the same structure described for program 7(a).  All three data components need 
to be loaded into WinBUGS for the program to run. Note that, because two separate sets of 
data are being read into WinBUGS, the variable names referring to the arm-level data have 
the added suffix .a, to distinguish them from the trial-level data.  
# Data (Parkinson’s example: Arm and Trial-level data) 
list(ns.a=3, ns.t=4, nt=5)    
 
# Arm-level data 
t.a[,1] t.a[,2] t.a[,3] y.a[,1] y.a[,2] y.a[,3] se.a[,1] se.a[,2] se.a[,3] na.a[] # study 
1 3 NA -1.22 -1.53 NA 0.504 0.439 NA 2 # 1 
1 2 NA -0.7 -2.4 NA 0.282 0.258 NA 2 # 2 
1 2 4 -0.3 -2.6 -1.2 0.505 0.510 0.478 3 # 3 
END 
 
# Trial-level data 
t[,1] t[,2] y[,2] se[,2] na[] # study 
3 4 -0.35 0.441941738 2 # 4 
3 4 0.55 0.555114559 2 # 5 
4 5 -0.3 0.274276316 2 # 6 
4 5 -0.3 0.320087245 2 # 7 
END 
 
# Initial Values  
# Initial values for delta can be generated by WinBUGS. 
#chain 1 
list(d=c( NA, 0,0,0,0), sd=1, mu=c(0, 0, 0)) 
#chain 2 
list(d=c( NA, -1,-3,-1,1), sd=4, mu=c(-3, -3, -3)) 
#chain 3 
list(d=c( NA, 2,2,2,2), sd=2, mu=c(-3, 5, -1)) 
 
The parameters to monitor are the same as in Example 5. 
Program 8(b):  Normal likelihood, identity link, shared parameter model, Fixed Effects 
(Parkinson’s shared parameters) 
# Normal likelihood, identity link, Arm and Trial-level data (treatment differences) 
# Fixed effects model 
model{        # *** PROGRAM STARTS 
for(i in 1:ns.a){      # LOOP THROUGH STUDIES WITH ARM DATA 
    mu[i] ~ dnorm(0,.0001)     # vague priors for all trial baselines 
    for (k in 1:na.a[i]) {      #  LOOP THROUGH ARMS 
        var.a[i,k] <- pow(se.a[i,k],2)    # calculate variances 
        prec.a[i,k] <- 1/var.a[i,k]     # set precisions 
        y.a[i,k] ~ dnorm(theta[i,k],prec.a[i,k])   # normal likelihood 
        theta[i,k] <- mu[i] + d[t.a[i,k]] - d[t.a[i,1]]   # model for linear predictor 
        dev[i,k] <- (y.a[i,k]-theta[i,k])*(y.a[i,k]-theta[i,k])*prec.a[i,k]    #Deviance contribution 
      } 
    resdev[i] <- sum(dev[i,1:na.a[i]])     #  summed residual deviance contribution for this trial 
  } 
for(i in 1:ns.t){      # LOOP THROUGH STUDIES WITH TRIAL DATA 
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    for (k in 2:na[i]) {     #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)      # calculate variances 
        prec[i,k] <- 1/var[i,k]    # set precisions 
        y[i,k] ~ dnorm(theta[i+ns.a,k],prec[i,k])   # normal likelihood 
        theta[i+ns.a,k] <- d[t[i,k]] - d[t[i,1]]     # model for linear predictor 
        dev[i+ns.a,k] <- (y[i,k]-theta[i+ns.a,k])*  #Deviance contribution 
                         (y[i,k]-theta[i+ns.a,k])* prec[i,k] 
      } 
    resdev[i+ns.a] <- sum(dev[i+ns.a,2:na[i]])   #  summed residual deviance contribution for this trial 
  }    
totresdev <- sum(resdev[])     #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) }   # vague priors for treatment effects 
}       # *** PROGRAM ENDS  
 
# Initial Values  
#chain 1 
list(d=c( NA, 0,0,0,0), mu=c(0, 0, 0)) 
#chain 2 
list(d=c( NA, -1,-3,-1,1), mu=c(-3, -3, -3)) 
#chain 3 
list(d=c( NA, 2,2,2,2), mu=c(-3, 5, -1)) 
 
RESULTS 
Results (based on 3 chains: 100,000 iterations after a burn-in of 20,000 and 50,000 for the FE 
and Re models, respectively) are presented in Table A9 and are the same as the results 
obtained using the model in Example 5. 
 
 
